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PART I. Identification of Novel Aberrantly Methylated CpG Islands in 
Childhood ALL 
Aberrant promoter hypermethylation is recognized as a hallmark of human 
malignancies. This aberration leads to transcriptional inactivation of cancer-related 
genes, and thus malignant transformation. Currently, candidate gene approach is 
commonly used for the investigation of DNA methylation involvement in various 
human cancers. By this approach, it was demonstrated that aberrant DNA 
hypermethylation plays a significant role in leukemogenesis. 
To identify novel cancer-related genes in childhood acute lymphoblastic 
leukemia (ALL), we carried out a genome-wide screening for aberrantly methylated 
CpG islands by studying and comparing the methylation patterns of patient leukemic 
samples (N=8; 4 pre-B ALL, 2 common-ALL and 2 T-cell ALL) and normal 
peripheral blood (N=4) using methylation-sensitive arbitrarily primed polymerase 
chain reaction (MS-AP PGR). We found 40 genomic regions showing differential 
DNA methylation patterns between the leukemic and normal samples. DNA 
1 
sequencing and BLAT search revealed 10 of them were located either at or near by the 
5' putative promoter regions with dense CpG islands of known genes (N=9) and 
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uncharacterized gene (N=l). Among these candidates, Fibrillin 2 (FBN2), located on 
chromosome 5q23.1, was selected for further study as it demonstrated concurrent 
aberrant promoter hypermethylation (697，CCRF-CEM, MOLT-3, REH and Rs4;ll) 
and transcriptional silencing (CCRF-CEM, MOLT-3 and Rs4;l) or down-regulation 
(697) in all 5 ALL cell lines except REH, which showed FBN2 expression despite 
presence of promoter methylation. Using bisulfite sequencing analysis, we 
demonstrated a strong correlation between FBN2 methylation density and the gene 
expression in ALL cell lines. High methylation density was found in the ALL cell 
lines with loss or reduced gene expression, whereas REH with normal expression 
revealed low methylation density. 
PART II. Methylation Studies of FBN2 in ALL Cell Lines and Clinical Samples 
of childhood ALL 
We performed demethylation studies and demonstrated that treatment by 
5-aza-2‘ -deoxycytidine on the FBN2 non-expressing or down-regulated cell lines 
induced a dose-dependent reactivation (CCRF-CEM, MOLT-3 and Rs4;ll) or 
up-regulation (697) of FBN2 expression, thus confirming the role of promoter 
methylation in transcriptional silencing of FBN2. 
� FBN2 is a large modular extracellular matrix glycoprotein that functions as a 
ii 
Thesis Abstract 
beta-1 integrin ligand for cell adhesion. It is possible that it may play a role in the 
cellular interactions that are important in ALL biology in the bone marrow 
microenvironment. Next, we studied the involvement of FBN2 hypermethylation in 
clinical leukemic samples and found 69 % (44/64) of childhood ALL samples 
revealed this aberration (B lineage ALL: 66 % [38/58]; T lineage ALL: 100 % [6/6]). 
In addition, in these leukemic samples, we demonstrated concordant findings of loss 
or down-regulation of FBN2 mRNA by semi-quantitative RT-PCR and 
hypermethylated status by COBRA analysis. 
Taken together, we successfully demonstrated the feasibility of MS-AP PCR in 
the identification of novel DNA methylation-regulated genes in leukemogenesis and 
our results suggested DNA hypermethylation associated FBN2 silencing may be 
potentially involved in the pathogenesis of childhood ALL. In view of the high 
frequency of FBN2 promoter hypermethylation, this aberration may also prove to be a 






























化和訊息核糖核甘酸抑制(CCRF-CEM ‘ M0LT3 ‘ Rs4;ll)或下調（697)的細胞 
株作重新表達。這個結果證實了 FBN2訊息核糖核甘酸的抑制或下調是由啓動子 
異常甲基化機制所控制。因此，我們進一步探討了 FBN2的異常甲基化在兒童急 
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Chapter 1 Introduction 
Chapter 1 Introduction 
1.1. Normal Hematopoiesis 
Hematopoiesis is the process of blood cell development that occurs in bone 
marrow (BM) of adults and children after birth. The continuous production of blood 
cells during the entire life span of an individual depends on a type of rare 
pluripotential cell, hematopoietic stem cell (HSC), whose abundance is tightly 
regulated by several processes, including self-renewal, proliferation, lineage 
specification, differentiation, maturation and apoptosis (Rafii et al, 1997). Through 
the intrinsic cellular programming, cytokine signaling and interaction between 
adhesive molecules with the micro-environmental stroma, primitive HSC vigorously 
divides and differentiates into various types of blood cells, which, however, can be 
generalized into two major descendents, the myeloid and lymphoid lineages 
(Hoffbrand et cd., 2001). In particular, the myeloid lineage includes eosinophils, 
basophils, neutrophils, megakaryocytes, erythrocytes and monocytes. The lymphoid 
lineage, on the other hand, includes B lymphocytes, T lymphocytes and natural killer 
(NK) cells (Figure 1.1) (Orkin, 1995). 
t 
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Figure 1.1 A schematic diagram of normal hematopoiesis. 
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1.2. Hematological Malignancy and the Aberrant Development of Blood 
Cells 
Hematological malignancy arises when the normal regulatory processes of 
hematopoiesis lose its control, accumulating aberrant blood cells in bone marrow and 
circulation (Downing and Shannon, 2002). The prevalence of hematological 
malignancies is estimated to 5 % - 8 % in adult cancers and over 50 % in childhood 
cancers (American Cancer Society, 2005). Previous report has demonstrated that 
certain unknown factors induced the transformation of HSC into rare leukemic stem 
cells (LSC) that render the maintenance and acquisition of uncontrolled hematopoiesis 
and therefore hematological malignancy (Hoffbrand et al., 2001). More recent report 
2 
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has suggested that the pluripoitency of HSC enables the cell to possess unlimited 
self-renewal property and to lengthily persist for the accumulation of aberrant genetic 
changes, allowing the derivation of LSC from HSC (Bonnet, 2005). Besides, the 
common developmental pathways of HSC and LSC may also be one of the factors for 
such unknown cause of transformation (Huntly and Gilliland, 2005) (Figure 1.2). 
Figure 1. 2 Origins of leukemic transformation events. 
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1.3. Leukemia and Its Classification 
Leukemia, respectively affect 31 % and 25 % of cancer patients aged under 15 
and 20 years old, is the commonest type of hematological malignancy that observed in 
3 
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children (SEER Cancer Statistics Review, 2005; Pui and Evans, 1998; Pui, 2000) 
(Figure 1.3). It can be divided into acute and chronic types according to the degree of 
maturity of the predominant leukemic cell type. Specifically, acute leukemia is a 
rapidly progressing disease that impaired cellular functions of mostly the immature 
blood cells. Chronic leukemia, as implied from its name, progresses slowly as it 
affects cell types that are better differentiated, thereby more capable in retaining their 
normal functions (Hoffbrand et al, 2001). Based on their involvement in the 
hematopoietic cell lineages, acute and chronic leukemia can be subdivided into four 
distinct groups, namely acute lymphoblastic leukemia (ALL), acute myeloid leukemia 
(AML)，chronic lymphoid leukemia (CLL) and chronic myeloid leukemia (CML) 
(Hoffbrand et a!., 2001) (Table 1.1). 
% 
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Figure 1. 3 Approximate distribution of childhood and adult leukemias. 
• a l l HamlDcll Dcml 
Childhood Adult 
ALL: 77.6% ，1 
AML: 35.3% 
/ � ^ 3 % CLL: 42.9% ‘ 
i / ‘ CML: : 
, / AML: 190/0 J 
(Calculatedfrom "Cancer Facts Figures, 2005, American Cancer Society" [Numbers do not add up to 
100 because of rounding.]) 
Table 1. 1 Predominant abnormal cell types in four major types of leukemia. 
Types of leukemia Predominant leukemic cells 
in BM and blood 
Acute lymphoblastic leukemia (ALL) Lymphoblasts 
Acute myeloblastic leukemia (AML) Myeloblasts 
Chronic lymphoid leukemia (CLL) Lymphocytes 
Chronic myeloid leukemia (CML) Neutrophils, basophils, eosinophils, 
mekakaryocytes 
1.4. Childhood Acute Lymphoblastic Leukemia (ALL) 
1.4.1. Epidemiology 
Among the four groups of leukemia, ALL is the most prevalent in childhood 
(Figure 1.3); among the childhood ALL cases, abnormal clones originating from B 
5 
Chapter 1 Introduction 
progenitor cells represents 80 % -85 % cases while the remaining 1 5 % - 20 % clones 
are derived from T progenitor cells (Poplack, 1993). The prevalence of ALL is 
particularly high in developed countries such as Italy, the United States, Switzerland 
and Costa Rica (SEER Cancer Statistics Review, 2005). In United States, the annual 
incidences of ALL are 6.1 per million in American white children and 5.1 per million 
among the American black children (Chan and Pui, 2003). In Hong Kong, we have a 
similar incidence at 4 per million children, in other words; roughly 50 to 60 children 
are diagnosed to suffer from leukemia every year (Children Cancer Foundation, Hong 
Kong). On the other hand, the occurrence of childhood ALL peaks at two to five years 
old (SEER Cancer Statistics Review，2005). In addition, the prognosis for girls with 
ALL is slightly better than for boy ALL patients (SEER Cancer Statistics Review, 
2005); and ALL white children survive better than ALL black children (Chessells, 
1995)，though the causes are still relatively unknown (Redaelli et al, 2005). 
1.4.2. Causes and R isk Factors 
As in all types of cancers, both environmental factors (e.g. exposure to 
carcinogens) and genetic elements (e.g. up-regulation of oncogenesis or 
down-regulation of tumor suppressor genes) participate in the development of ALL 
(Balmain et al, 2003). Table 1.2 summarized the current knowledge about the causes 
6 
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of childhood ALL. However, precise etiology of children ALL is still unknown, as 
previous studies have only examined risks factors of general ALL, imexploring the 
specific ALL lineage and subtype. There is little evidence to show a strong association 
between the environmental factors and the development of ALL, though many 
investigators have attempted such correlation. Other suggestive factors such as old 
maternal age, maternal smoking during pregnancy and high birth weight have been 
reported, but the evidence are neither strong nor conclusive (Sandle and Ross, 1997; Ji 
et al., 1997; Hjalgrim et al” 2003). 
Table 1. 2 Current knowledge about the risk factors of childhood ALL. 
Factor Example Reference 
Genetic factors (known risk factors) 
Genetic disease Down Syndrome patient has 20-fold Arced , 2002 
increase risk 
Siblings or identical twins Siblings or identical twins of affected child Sandler and Ross, 1997 
have 2 to 4 times greater risk 
Environmental factors (potential risk factors) 
Ionizing Radiation X-ray exposure during pregnancy Shu et al., 2002 
Chemical Benzene, trichloroethylene Schnatter et al, 2005 
1.4.3. Molecular Pathophysiology 
i 
ALL, resulting from the clonal expansion of genetically and abnormally altered 
lymphoid progenitor cells (Armstrong and Look, 2005), can be characterized by the 
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rapid accumulation of primitive leukemic blasts in the bone marrow which 
subsequently invades many tissues, including liver, spleen, lymph nodes, and central 
nervous system (CNS) (Spiegel et al., 2004). Severe anemia, thrombocytopenia of 
marked bleeding and great susceptibility to infection are resulted when the abnormal 
blasts replace normal bone marrow in bone and normal leukocytes in circulation 
(Hoffbrand etal., 2000). 
The role of oncogenes on the induction and maintenance of malignancy is crucial. 
It has been found that chromosomal translocations, which itself can cause 
chromosomal abnormalities and thereby the production of oncogenes, are present in 
as many as 75 % of ALL cases (Armstrong and Look, 2005). Besides, the use of 
molecular analysis in identifying chromosomal aberrations has also solidified the 
notion that chromosomal abnormalities are unique to leukemias. These abnormalities 
lead to differentiation arrest and aberrant growth of leukemic cells. The identification 
of chromosomal translocations provides a foundation of the molecular pathogenesis of 
ALL. The details of chromosomal aberrations found in childhood ALL will be 
discussed in section 1.4.6.2. 
In 1983, the involvement of a tumor suppressor gene in the formation of 
retinoblastoma is firstly proposed (Benedict et al, 1983)，since then, a growing 
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number of tumor suppressor genes have been discovered as the contributors in 
tumorigenesis. Tumor suppressor genes are altered via different mechanisms, 
including deletions and point mutations, which may result in an inactivation of 
particular protein (Stanbridge, 1990). Epigenetics regulation of the tumor suppressor 
gene can also blunt its expression (Garinis, 2005). A broad spectrum of tumor 
suppressor gene alterations do occur in ALL, especially structural alterations of 
retinoblastoma suppressor gene (Rb) gene (Sauerbrey et al, \99%),pl5 (Cayuela et al.’ 
1996%pi4 (Faderl et al,, 1999) andp53 (Sugimoto et al., 1991). 
1.4.4. Clinical Presentation 
Acute leukemia is defined as the presence of over 30 % of blast cells in the BM 
at clinical presentation (Kojima et al., 1990). The diagnosis of ALL requires general 
physical examinations (chest X-ray of thymus and lumbar puncture) and BM 
assessments (complete blood count analysis, cytochemical and morphological 
evaluation, immunophenotyping, cytogenetics and molecular genetic analysis) 
(Gilliland and Tallman, 2002). 
The symptoms of ALL are fairly non-specific. The most common features of 
childhood ALL are lymphadenopathy, hepatomegaly, splenomegaly and fever. Other 
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clinical features of ALL include anemia and hematostatic dysfunction (Pui, 2001). 
1.4.5. Classification 
1.4.5.1. Immunophenotyping 
Most leukemic cells share similar features with normal lymphoid precursors, 
since then, the use of combinatory immunological markers is useful to sub-classify B 
lineage ALL and T lineage ALL into different subtypes (General Hematology Task Force 
of the BCSH, 1994; Farahat et al., 1995; Bene et al” 1998). The B lineage ALL is 
characterized by the expression of at least two of the B-cell antigens CD 19, CD79a or 
cytoplasmic CD22 with lack of expression of T and myeloid cell markers. In addition, 
B lineage ALL is sub-classified into two main types: precursor B-cell derived ALL 
and B-ALL (also known as Burkitt's leukemia) (Ludwig et al, 1994). The precursor 
B-cell ALL is further subtyped by immunophenotyping: pro-B ALL, early precursor-B 
cell (early pre-B) ALL, common ALL and precursor-B (pre-B) ALL. T lineage ALL, 
whose shows expression of T-cell antigens like CD7 and cytoplasmic CD3 is 
sub-classified into four subtypes: pre T-ALL, early T-ALL, intermediate T-ALL and 
mature T-ALL (Ludwig et al.’ 1994). The specific markers used to distinguish ALL 
subtypes are illustrated in Figure 1.4. 
� Generally, precursor B-cell ALL have a more favorable prognosis than others 
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B-ALL and T lineage ALL. However, there are still subsets of B-cell precursor ALL 
patients come with poor prognosis such as those patients having CD 10 positive 
expression (Pui, 1995). 
Immunophenotyping can be used to detect morphologically and cytochemically 
unclassified ALL. In particular immunophenotyping is a major factor in determining 
the chemotherapy protocol of a patient (Coustan-Smith et al, 2000). Flow cytometry, 
an important individual cell monitoring technology nowadays, allows the detection of 
minimal residual disease (MRD) which is particularly important in identifying 
prognostic groups and distinctive individualized treatment of a ALL patients (Mortuza 
et al, 2002). The concepts of MRD are defined as malignant cells that cannot be 
detected by morphological examination but can be identified with newer technology 
instead (Dworzak et al., 2002). The advantage of using multi-parametric flow 
cytometry is its capability in detecting 1 leukemic cell among 10000 normal cells, 
permitting precise immunophenotypic characterization of leukemic cells even the 
malignant cells are in low numbers (Riley et al, 2002). 
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Figure 1. 4 Sub-classification of ALL. 
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(TdT+, CD19+, CD79a+’ CD22+) 
f Pro-B Early pre-B C^ommon ALL Pre-B B ALL 
# - # - # — • 
CD 10- CD 10- CD10+ cytoplasmic surfacc lgM+ 
IgM+ 
T lineage ALL 
A (CD2+, CD7+，cy CD3+) 
Lymphoid pro-T ALL Prc-T ALL Intermediate Mature T ALL 
progenitor 丁 八乙^ 
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(Summarized from Ludwig et al, 1994) 
1.4.5.2. French-American-British (FAB) Classification 
Childhood ALL patients can be categorized into three major risk groups, 
namely, standard risk, intermediate risk and high risk group, according to some known 
prognostic factors such as white blood cell (WBC) count, age, immunophenotype, 
genetic aberrations and early response to treatment (Friedmann and Weinstein, 2000; 
f 
yeoh et al, 2002). 
The French-American-British (FAB) classification has been introduced for more 
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than 25 years. It is based on the morphological, cytochemical and immunophenotypic 
presentation of ALL and AML (Bennett et al, 1976). This classification, together with 
clinical presentations, is a useful predictor for preliminary diagnosis of ALL and help 
to establish patient's risk profile (Table 1.3). The FAB classification system has been 
adopted internationally. Another classification system developed by the World Health 
Organization (WHO) includes cytogenetics molecular genetics data, as well as 
morphology and immunophenotyping (Mathe and Rappaport, 1976; Harris et al, 
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Table 1. 3 FAB classification of ALL 
一 LI L2 L3 “ 
— F r e q u e n c y 80% 17% 3 % 
Cell size Small and Large, often Large, 
homogeneous heterogeneous heterogeneous 
Amount of Scant Moderately Moderately 
cytoplasm abundant abundant 
Nucleoli Small and not Numerous and Present and may be 
prominent prominent prominent 
Cytoplasmic Variable Variable Prominent 
vacuoles 
Immunophenotype B-cell or T-cell B-cell or T-cell Mature B- cell 
association precursor precursor (Burkitt's disease) 
Representative - ^ ^ ^ B ^ H H 
(Summarized from Pui and Crist, 1994; Mckenna, 2000) 
1.4.6. Diagnosis and Prognosis 
Prognostic features play a critical role in the effectiveness of childhood ALL 
therapy. It is important to know the risk group of childhood ALL patient in order to 
plan individualized treatment (Friedmann and Weinstein, 2000). Advances in 
medicine have improved the prognosis of children ALL from 15 % in the late 1960s 
to approximately 80 % in some cases today (Pui et al, 2004). Recent findings have 
1 
shown that the prognosis of pediatric ALL patients are usually better when compared 
to adult patients (Pui et al., 2004), as only 60 % adult ALL patients can achieve 
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long-term disease-free survival (DFS) (Redaelli et al.’ 2005; Hoelzer and Gokbuget, 
2000). The poor outcome in adult ALL has been attributed to the increased toxicity of 
drugs, the lower tolerable doses and shorter cycles of treatment (Thomas et al., 2001). 
Studies have suggested different disease biology, host features, treatment strategies, 
early response to treatment, specific subtype and age are the leading reasons for such 
varied treatment response between the pediatric and adult ALL patients (Downing and 
Shannon, 2002). 
Although the prognostic factors based on age and WBC count act as a powerful 
predictors of disease outcome, there are still 20 % of standard risk childhood ALL 
patients destined to relapse by current therapy (Pui and Evans, 1998). Therefore, 
scientists have moved to investigate the prognostic significances based on better 
refined immunophenotypes and genetic features. The prognostic impact of these 
factors will be discussed in this section. 
1.4.6.1. Morphological and Cytochemical Analysis 
The diagnosis of ALL can usually be achieved by careful morphological 
assessments of BM aspirate smear (Figure 1.5) (Tosi et al., 1987). Moreover, 
cytochemical analysis is often used to distinguish poorly differentiated ALL. Table 1.4 
shows the morphological and cytochemical profiles of ALL (McKenna, 2000). 
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( 
Figure 1. 5 Micrbscopic examination of normal and ALL BM specimens. 
The blast cells in ALL patients are relatively small, have condensed chromatin and 
little cytoplasm. These morphological features are typical case of ALL. 
^ N o f f a a l j t j ^ ^ ^ j l J： . A L L B ^ 飞 , 
(Adaptedform the website http://www-sdc.med.nagasaki-u.ac.jp/n50/disaster/Leukemia-E.html) 
Table 1. 4 The morphological and cytochemical profiles of ALL patient. 
Morphological profile 
Blast size Small to medium; variable in size 
Chromatin Rather coarse 
Nucleoli Absent or one or two; indistinct 
Cytoplasm Scant or moderate 
Auer rods Absent 
Myelodysplasia Absent 
Cytochemical profile 
Myeloperoxidase and Sudan Black B Negative 
Non-specific esterase Focal; not definitive 
Periodic acid Shiff (PAS) Positive; 75 % 
Acid-phosphatase Positive in T-ALL 
(Summarizedfrom Hoffl)rand et al, 2001 andMcKenna, 2000) 
1.4.6.2. Cytogenetic and Molecular Genetic Characterizations 
Cytogenetic and molecular techniques has been begun to contribute in the 
t 
diagnosis, prognosis and classification of ALL (Table 1.5). Cytogenetics techniques 
that are adapted for current clinical usage include fluorescence in situ hybridization 
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(FISH), spectral karyotyping (SKY) and comparative genomic hybridization (CGH) 
(Gilliland and Tallman, 2002). Specifically, a wide variety of translocations in ALL 
were occurred via: (1) deregulation of an intact gene by disruption or removal, (2) 
replacement of the adjacent controlling elements and (3) creation of a new fusion 
gene. 
Approximately one-third of ALL blasts shows an increased chromosome 
numbers (e.g. hyperdiploid, >47 or >50 chromosome). Besides, one-third of the ALL 
blasts show chromosomal translocations (Carroll et al., 2003). The most commonest 
rearrangements in childhood ALL are illustrated in Table 1.6. TEL-AMLl 
translocation is the most prevalent molecular cytogenetics abnormality in childhood 
ALL (Downing and Shannon, 2002). 
Genetic abnormalities found in the ALL blasts provide an insight into the 
prognosis of ALL especially the prediction of sensitivity towards chemotherapeutic 
agents (Raimondi, 1993; Zwaan et al, 2002). For example, in terms of disease 
biology of precursor B-cell ALL, TEL-AMLl translocation is the most prevalent 
genetic abnormalities among pediatric patients and these patients can usually be cured 
with chemotherapy alone (Krishna et al., 2001). However, in adult precursor B-cell 
« 
ALL, investigators have observed high percentage of BCR-ABL fusion, which is 
known to possess a strong chemoresistant behavior that can diminish chemotherapy 
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response in adult patients (Westbrook et al., 1992). 
More recent report demonstrates the chromosomal rearrangement across llq23 is 
associated with a poorer prognosis and it contributes to 75 % of infant ALL cases (Pui 
et al, 2002). In particular, the presence of Philadelphia chromosome in Ph ALL 
patients has the worst prognosis among all childhood leukemias, and recurrence 
usually occurs in these patients (Arico et al, 2000). 
Table 1. 5 The relationship between cytogenetics and prognosis of ALL. 
Prognosis Types of chromosomal abnormalities 
Standard risk Hyperdiploidy >50 
TEL-AMLl rt(12;21)(pl3;q22)) 
Intermediate risk Standard risk in age and WBC without 
significant genetic risk features 
High risk E2A-PBX(X{\-,\9){c(n-,c{U)) 
T lineage ALL 
High risk in age and WBC without 
significant genetic risk features 
Very high risk BCR-ABL (t(9;22)(q34;qll)) 
MLL rearrangement 
(Summarized from Armsstrong and Look, 2005; 2000 and McKenna, 2000) 
% 
18 
Chapter 1 Introduction 
Table 1. 6 Commonest chromosomal translocations in childhood ALL. 
Chromosomal Predominant types 
Fusion genes Frequency Reference 
translocation of leukemia 
t(12;21)(pl3;q22) TEL-AMU Precursor B-cell 2 2 % Golub etai, 1995 
ALL 
t(4;ll)(q21;q23) MLL Infant ALL 8 % Pui etal., 2002 
t(l;19)(q23;ql3) E2A-PBX Pre-B ALL 5 % Uckun etal., 1998 
t(9;22)(q34;qll) BCR-ABL PhALL 3 % Hilden and Kersey, 1994 
TALI deletion SIL-TALl T-ALL 2 0 % Hoelzer, 2002 
1.4.7. Treatment 
Different types of treatments are used for treating childhood ALL. These include 
chemotherapy, radiation therapy and stem cell transplantation (Pui, 1998). Most 
chemotherapy treatment protocols include three phases: induction, intensification and 
maintenance phases (Table 1.7.) (Redaelli et al, 2005). These three phases create a 
complete remission of 99 % (Pui and Evans, 1998). The CNS is the second most 
frequent site of leukemia relapse besides BM. Therefore, CNS prophylaxis is given 
during each phase of therapy to kill leukemic cells in the CNS (Dritschilo et al., 
1976). 
The latest chemotherapy regimen is adopted from the HKALL97 protocol, 
developed by the Hong Kong Pediatric Hematology and Oncology Study Group. This 
« 
protocol is originated from the German Berlin-Frankfiirt-Muenster 95 (BFM95) 
protocol that includes a delayed intensification similar to the induction phase repeated 
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5 months after diagnosis (Li et al., 2006). This protocol has demonstrated a decreased 
relapse rate compared to previous protocols (15.7 % vs. 37.3 %; /7<0.001) (Li et al, 
2006). 
For instance, 40 % of childhood ALL patients fall into low risk group and they 
often require lower dose of chemotherapy, less toxic medications and less intensive 
CNS prophylaxis. However, around 9 % of childhood ALL patients fall into the high 
risk group and they will be subjected to stem cell transplantation (Rubnitz and Look, 
2000). 
Table 1. 7 Three phases of chemotherapy for childhood ALL patient. 
Phases Description Medications used 
Induction phase This phase intends to kill Steroids (prednisone, 
leukemic cells in BM and prednisolone, 
blood. dexamethasone) 
Intensification phase It begins after complete Methotrexate, 
remission and is used to 6-mercaptopurine, 
kill any remaining L-asparginase, 
inactive leukemic cells to dexamethasone, 
prevent relapse. vincristine, doxorubicin, 
thioguanine and 
cytarabine. 
Maintenance phase It is used to kill any Methotrexate, 
residual leukemic cells 6-mercaptopurine 
that would proliferate and 
cause relapse. 
CNS prophylaxis Includes intrathecal Methotrexate and 
chemotherapy and cytarabine 
radiation 
(Summarizedfrom Redaelli et al., 2005) 
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1.5. Overview of Epigenetics 
The principle and mechanism of Epigenetics was firstly introduced in 1983 
(Feinberg and Vogelstein, 1983; Gama-Sosa, 1983). Epigenetic inheritance is defined 
as cellular information, other than the DNA sequence itself that is heritable during cell 
division, in other words, is capable to alter the gene expression without a change in 
nucleotide sequence (Feinberg and Tycko, 2004). 
In the succeeding years, the concept of epigenetic has become more prevalent 
when researchers have further demonstrated the participation of epigenetic events in 
many physiological and pathophysiological conditions, as implied from human 
cancers (Reik et al.’ 2001; Laird, 2005). Epigenetics involves three mechanisms: DNA 
methylation, post-translational modification of histone (methylation, phosphorylation 
and acetylation) and chromatin alteration (modification of protein binding molecules) 
(Gius, 2005). These mechanisms may take part in tumorigenesis either through the 
inactivation of tumor suppressor genes or the activation of oncogenes (Osada and 
Takahashi，2002; Esteller, 2006) (Figure 1.6). 
4 
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Figure 1. 6 Epigenetic regulation of gene expression in tumorigenesis. 
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1.6. Concepts of DNA Methylation 
Cytosine DNA methylation is the commonest epigenetic events in the 
mammalian genome. DNA methylation, occurring primarily at the cytosine residue at 
5'-CG-3' nucleotides, has important roles in the regulation of gene expression, 
genomic imprinting, as well as silencing of repeating elements in the genome. 
1.6.1. CpG Islands 
CG site is a dinucleotide sequence of 5'-CG-3' that can be found throughout the 
vertebrate genome, though presents at a relatively low frequency. It has been reported 
that the actual presence of 5'-CG-3' dinucleotide sequences occurred within 5% to 10 
% of its predicted frequency due to the high mutability of methylated cytosine (Das 
and Singal, 2004). 
CpG islands, a cluster of CG sites firstly described in 1987 by Gardiner-Garden 
and Frommer, is a region longer than 200bp with GC content greater or equal to 50 % 
and a CpG observed/expected ratio greater or equal to 0.6 (Gardiner-Garden and 
Frommer, 1987). It can be found occasionally throughout the human genome. A CpG 
island is usually kept unmethylated with the exception of inactive chromosome X in 
females. In mammal, approximately 60 % of the gene promoters are co-localized with 
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a CpG island which suggests its importance in the regulation of a particular gene 
(Antequera, 2003). 
1.6.2 Mechanisms of DNA Methylation 
DNA methylation is a covalent modification of nucleotides, in which a 
methyl group is transferred from .S-adenosylmethionine (SAM) to the carbon-5 
position of cytosine by DNA-methyltransferases (DNMTs) (Vilkaitis et al., 2001) 
(Figure 1.7). The underlying mechanism of DNA methylation is still controversial. ( 
There are three proposed mechanisms to account for the transcriptional repression by 
DNA methylation. 
The first mechanism involves a direct interaction between specific transcriptional 
factors (AP-2, c-Myc/Myn, cyclic AMP-dependent activator C R E B , E 2 F and N F K B ) 
with their DNA recognition sites at the corresponding promoter sequence. These 
transcriptional factors have a recognition site that recognizes 5'-CG-3' dinucleotide. It 
has been shown that methylation can inhibit the interaction between transcriptional 
factors and the promoter sequences (Figure 1.8-A) (Tate and Bird, 1993). 
The second possible mechanism is the involvement of direct binding of specific 
1 
transcriptional repressors to methylated DNA sequence. This interaction is mediated 
by methyl cytosine binding proteins (MeCP), which targets the 5' methylated CpG 
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sequence (Prokhortchouk and Hendrich, 2002). These proteins include MeCPl, 
MeCP2, methyl-CpG binding domain protein (MBD) 1’ MBD2, MBD4 and Kaiso 
(Figure 1.8-B) (Das and Singal, 2004). 
The third mechanism suggests that DNA methylation can mediate histone 
modification and chromatin structure and hence altering gene expression. The 
acetylation status of the histone plays an important role in the transcriptional 
regulation (Fraga and Esteller, 2005). Being the major component of chromatin, 
histone can be acetylated or deacetylated by histoneacetylases (HATs), the gene 
activator, or histonedeacetylases, the gene repressor (HDACs), respectively 
(Kouzarides, 2002; Gnmstein, 1997). MBD proteins and DNMTl recruits HDACs to 
the methylated promoter. Also, methylation of histone-H3-lysine 9 (H3-K9) by 
histone methylases is associated with chromatin condensation and suppression of gene 
expression (Nakayama et al, 2001). This model suggests that DNA methylation not 
only prevents the activation of gene by blocking the access of transcriptional factors 
but also stabilizing the transcriptionally inactive state of chromatin (Singal and Ginder, 
1999) (Figure 1.9). 
However, it is now realized that hypermethylation at CpG island is just one of 
1 
the consequences of an integrated change in chromatin structure and histone 
modifications (Lund and van Lohuizen, 2004). Nevertheless, the understanding of the 
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status of DNA methylation is a useful marker for assessing the epigenetic state of a 
locus, because it is preserved in DNA isolated from cell, and can be measured by 
PCR-based techniques easily. 
Figure 1. 7 Conversion of cytosim to 5 '-methyl-cytosine by DNMT. 
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Figure 1.8 The two proposed DNA methylation mechanisms regulating the 
transcriptional repression by transcription activators and repressors. 
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Figure 1. 9 Chromatin modulation mediated by DNA methylation. 
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1.6.3 Physiological Roles of DNA Methylation 
CpG islands are typically located at the 5' end of genes and are usually kept 
unmethylated. In contrast, the majority of methylated CpG islands are located within 
the repetitive elements including centromeric repeats, satellite sequences and gene 
repeats that encode ribosomal RNAs (Holmes and Soloway, 2006). Genomic 
imprinting and X-chromosome inactivation are the most prominent examples of 
methylation-regulating transcriptional repression in normal cells (Lyon, 1994). In this 
f 
section, the roles of DNA methylation in normal physiological development will be 
discussed. 
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The proper control of DNA methylation is responsible for genomic imprinting in 
normal embryonic development (Okano et al., 1999; Swales and Spears, 2005). 
Genomic imprinting is the parent-of-origin specific gene expression, whose controls 
allele-specific expression of the imprinted genes by means of DNA methylation. In 
other words, either the paternal or maternal allele is active for normal embryonic 
development. Approximately 80 imprinted genes have been identified and many of 
these imprinted genes are involved in regulating resource acquisition of the embryo 
and fetus (Horsthemke and Ludwig, 2005). For example, human small nuclear 
ribonucleoprotein polypeptide N {SNRPN) is highly methylated in oocytes but 
unmethylated in sperm. Specifically, hypermethylation of SNRPN was found to be 
proportional to oocyte diameter (Lucifero et al., 2004). 
X-chromosome inactivation，on the other hand, is another important biological 
significance of DNA methylation. The concept of X-chromosome inactivation is to 
inactivate one of the two female X-chromosomes so as to maintain chromosomal 
balance. Precisely, it ensures equivalent gene expression level between female and 
male. This stable inactivation has proven to be resistant to drug treatment and 
selection (Grant and Chapman, 1988). 
The degree of tissue-specific expression is also determined by DNA methylation. 
Maspin {SERPINB5), is a gene generally silenced in certain cell types including skin 
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fibroblasts, lymphocytes, bone marrow, heart or kidney. On contrary, it does express 
in epithelial cells, such as in airway, breast, skin, prostate and mouth. This silencing 
has shown to be unrelated to mutation or deletion. Therefore, hypermethylation of 
SERPINB5 turns out to be the cause of regulating tissue-specific expression (Futscher 
et al, 2002). 
DNA methylation at gene deficient regions, such as pericentromeric 
heterochromatin, plays a crucial role in maintaining the conformation and integrity of 
the chromosome (Ehrlich, 2000). Moreover, DNA methylation has also been proposed 
as a genomic defense system against mobile genetic elements like transposons and 
endogenous retroviruses. It appears as defense against the parasitic sequence elements, 
which constitutes more than 35 % of the human genome (Bestor, 1998). 
1.6.4 Initiation of A berrant DNA Methylation 
The over-expression of DNMTs likely contributes to the aberrant de novo 
methylation and also cancer development. The faulty repair mechanisms mediated by 
DNMTs may also introduce repairing errors and generate abnormal methylation 
patterns (Ramchandani, 1999). 
DNA methylation is mediated by three DNMT: DNMTl, DNMT3a and 
DNMT3b (Jones and Baylin, 2002). Aberrant DNA methylation may be caused by the 
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infidelity of DNMTl, and DNMTl has been shown to have higher affinity for 
hemimethylated DNA. It is believed that DNMTl is the primary enzyme responsible 
for copying methylation patterns from the parental to the daughter strand in DNA 
replication (Yokochi and Robertson, 2000). During DNA replication, methylation 
errors may be introduced and accumulated, causing hypermethylation. In particular, 
aging is a situation of this kind of progressive increase in the number of methylated 
CG dinucleotides (Issa, 2000). On the other hand, DNMT3a and DNMT3b have an 
equal affinity for unmethylated and hemimethylated DNA. However, they may target 
at the CpG sequence incorrectly and hence contribute to aberrant DNA methylation 
(Xie etal., 1999). 
1.7. DNA Methylation in Tumorigenesis 
The roles of DNA methylation had been extensively studied because of its 
contribution in tumorigenesis (Esteller，2002). The malignant cells show great 
discrepancies in DNA methylation status with normal cell. It is found that malignant 
cells have acquired global hypomethylation and regional hypermethylation was found 
in specific tumor suppressor genes (Figure 1.10). Aberrant DNA methylation have 
« 
been observed in several scenarios particularly in cancers, such as colon cancer, lung 
cancer, leukemia and ovarian cancer (Issa et al, 1993; Belinsky et al.’ 1996; Melki et 
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al, 1998; Ahluwalia et al., 2001). Numerous reports have demonstrated the 
consequences of promoter hypermethylation in suppressing or inhibiting gene 
expression (Esteller, 2002) (Table 1.8). Evidences have shown that the degree of 
methylation is inversely proportional to the expression of a particular gene (Singal 
and Ginder, 1999). Besides, hypomethylation also occurs in various subsets of cancers 
(Hoffmann and Schulz, 2005). 
Figure 1.10 Hypermethylation and hypomethylation. 
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Table 1. 8 The roles of genes commonly methylated in human cancers. 
Role of cancer . 
Gene Cancers involved Reference 
development 
r ‘ . ‘ , , Herman et al. Gastrointestinal 丨 
Cell cycle regulation CDKN2A/pl6 tract; Head and ' „ , 
I osncncz-v^cspcQcs 
nppk" 
• etai, 2000 
Dobrovic and 
DNA repair BRCAl Breast; ovarian ？ ‘ , 
^ 1997; Chaner al, 
i m 
Drug resistance ER Breast; prostate L^efaT ^2000^ ^ ‘ 
一 Detoxification GSTPl Prostate; renal Esteller etal, 1998 
Leukemia- Melki et al, 2000; 
Differentiation pl5 , , ‘ Herman et al, 
lymphoma ^^^^ 
Lui et al, 2005; 
Angiogenesis TIMP3 Breast; van der Velden et 
al., 2003 
Metastasis E-cadherin Throid; gastric Graff a/., 1998, 
^ Waki et al, 2002 
Abbreviations: BRCAl, breast cancer 1; CDKN2A/pl6, cyclin-dependent kinase 2A; 
ER, estrogen receptor; GSTPl ’ glutathione S-transferase PI; TIMP3, 
inetalloproteinase-3 
1.7.1. Regional Hypermethylation 
Regional DNA hypermethylation of a tumor suppressor gene was firstly 
discovered in retinoblastoma where the methylation status of the Rb was investigated. 
It was found that hypermethylation of the Rb gene was closely linked to the 
development of retinoblastoma (Greger et al., 1989). 
Methylation-regulating genes are those genes involved in cell cycle regulation, 
DNA repair, drug resistance, detoxification, differentiation, angiogenesis and 
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metastasis (Baylin and Ohm, 2006). Findings from several studies have shown that 
tumor cells can maintain the genetically defected allele while the other allele will be 
potentially inactivated by secondary causes. According to the Kundson's Two-hit 
Model, bi-allelic inactivation is required for the complete inactivation of a tumor 
suppressor gene (Knudson, 1996). The genetic inactivation of one allele may be due 
to the loss of heterozygosity (LOH), deletion, mutation or DNA methylation (Payne 
and Kemp, 2005). In addition to point mutation and deletion, promoter 
hypermethylation, on the other hand, is suggested to have an alternative role for 
transcriptional repression. Upon this circumstance, the remaining alleles will be 
inactivated, resulting in complete loss of a tumor suppressor gene and finally leading 
to the development of cancer. 
1.7.2 Global and Regional Hypomethylation 
Global hypomethylation has been shown to increase with the grade of 
malignancy (Feinberg and Vogelstein, 1983), whose has been found in cancers such as 
breast (Scares et al., 1999 ； Szyf et al.’ 2004), cervical dysplasia and carcinoma (Kim 
etcd.，1994). 
« 
Regional hypomethylation is the second most important DNA methylation defect 
which is observed in various malignancies and solid tumors, including hepatocellular 
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carcinoma (Saito et al., 2001)，cervical cancer (Kim et al.’ 1994), prostate tumor 
(Tokizane et al.’ 2005) and leukemias (Worton et al, 1991). Hypomethylation can 
contribute to oncogenesis by: (1) activation of oncogenes like cMYC and HRAS’ (2) 
activation of retrotransponson and (3) chromosomal instability (Cheah et al., 1984; 
Browett and Norton, 1989) (Figure 1.10). 
1.7.3 Microatellite Instability and Oncogeneic Mutation 
Besides global hypomethylation and regional hypermethylation, DNA 
methylation also contributes to microsatellite instability and mutational events during 
tumor progression (Figure 1.11 and 1.12). This phenomenon was first described in 
colorectal cancer relating mismatch-repair gene mutL homolog 1 (MLHl) (Kane et al, 
1997). The hypermethylation of MLHl promoter was found in colorectal cancer 
patients who have increased microsatellite instability when compared with normal 
individuals (Kane et al.’ 1997). It is suggested that hypermethylation does play a role 
in oncogenic mutation (Magewu and Jones, 1994; Greenblatt et al., 1994). For 
instance, 0^-methylguanine DNA methyltransferase (MGMT), is a DNA-repair gene 
which is silenced by mutational events with combination of the effect from DNA 
« 
hypermethylation in colon cancer. Hypermethylation of the MGMT promoter leads to 
increased G ^ A mutation (Esteller et al., 2000). Moreover, hypermethylation occuring 
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at the coding region of genes also increases the mutational rate (C+T transition, 
C C ^ T T mutation and G ^ T transversion mutation) due to spontaneous deamination, 
enhanced UV absorption and carcinogen binding near the methylated CpG (Jones and 
Baylin, 2002). An example is the hypermethylation ofp53 resulted in C ^ T transition 
(Greenblatt et al, 1994) (Figure 1.12). Mutation of p5S was found in 50 % of human 
cancers and 24 % of these mutations are due to hypermethylation induced C—T 
transition (Magewu and Jones, 1994). 
Figure 1. 11 Hypermethylation induced chromosomal instability. 
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2.1. Aberrant DNA Methylation in Childhood ALL 
Among different types of epigenetic mechanisms, DNA methylation has been 
studied extensively in the last few years as implied from the transcriptional silencing 
of tumor suppressor genes in various cancers (Baylin, 2005; Toyota and Issa, 2005; 
Galm et al, 2006). 
It has been found that DNA methylation does play an important role in acute 
lymphoblastic leukemia (ALL) tumorigenesis (Ponder, 2001; Pui et al, 1990). 
Therefore, the identification of aberrantly methylated genes is valuable for our 
understanding in childhood ALL pathogenesis. 
Candidate-gene approach has been adopted by most current methylation studies, 
which include investigation of a single gene or multiple genes concurrently 
(Roman-Gomez et al, 2004; Canalli et al, 2005; Yang et al.’ 2006). In addition, 
several studies have demonstrated the correction of aberrant gene methylation with 
the disease prognosis of childhood ALL, such genes are known as p21, protein 
phosphatase 1 (ASPPI), Calcitonin (CALCl), normal epithelial cell-specific 1 gene 
< 
(NESl) and large tumor suppressor, homolog 1 gene (LATSl) (Roman-Gomez et al.， 
2002; Agirre et al., 2006; Roman-Gomez et al.’ 2002; Roman-Gomez et al, 2004; 
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Jimenez-Velasco et al, 2004). Specifically, the multiple-genes approach is aimed to 
correlate the number of methylated genes with the risk prediction of ALL. 
Multivariate analysis investigating methylation profile of 15 target genes revealed 
shorter disease free survival (DFS) (p<0.0001) and overall survival (OS) (p=0.0004) 
in patients with >4 methylated genes (Roman-Gomez et a/.，2004). These results 
solidified the notion that the differences in DNA methylation of specific molecular 
pathways may contribute to the prognostic differences occurred in pediatric patients 
with ALL (Canalli et al., 2005). 
For instance, genes that are silenced by promoter hypermethylation may be 
involved in the inactivation of various biological pathways. Examples include: (1) 
down-regulation of cell cycle regulating molecules (Drexler, 1998), (2) inhibition of 
the apoptosis (Krug et al, 2002), (3) alteration of cell-cell adhesion (Roman-Gomez, 
et al. 2003) and (4) dysregulated expression of transcription factors, metabolic 
enzymes and other putative tumor suppressors (Roman-Gomez et al, 2003). 
In order to understand the importance of promoter hypermethylation in 
childhood ALL leukemogenesis, a comprehensive review on the functional aspects of 
methylation-regulated genes in childhood ALL will be discussed in this sections 
1 
(summarized in Table 2.1).-
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2.1.1. Cell Cycle 
Recent advances in cancer biology have clearly demonstrated the development of 
malignancies as well as their progression, are tightly linked to the alteration of 
molecular mechanisms in cell cycle (Park and Lee, 2003; Macaluso et al., 2006). Cell 
cycle represents a series of tightly integrated events regulating cell growth, cell 
proliferation and DNA repair. The alteration of cell cycle, and hence, the replication 
process is essential for the cancer progression. Cancers including solid tumors and 
hematological malignancies have been found to be caused by the dysregulation of cell 
cycle regulating molecules. In particular, cell cycle is positively regulated by cyclins 
and negatively regulated by cyclin-dependent kinase (CDK) inhibitors (Schwartz and 
Shah, 2005). 
pl5 and pl6 encode the CDK inhibitors which is capable to inhibit G1 phase 
progression. They compete with cyclin D for binding with CDK4/CDK6, in other 
words, inhibiting kinase activity of CDK4/CDK6 complex, resulting in 
dephosphorylation of Rb protein and G1 growth arrest (Furukawa, 2002). Promoter 
hypermethylation of pl5 has been found to range from 10 % to 67 % of childhood 
ALL patients by various studies (Wong et al, 2000; Roman-Gomez et al, 2004; 
< 
Canalli et al, 2005; Yang et al., 2006). Furthermore, OS was found to be diminished 
in pl5 hypermethylated adult ALL patients (Wong et al., 2000). In addition, the 
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occurrence of pl5 promoter hypermethylation in T lineage ALL is much more 
frequent in B lineage ALL (Tsellou et al., 2005; Iravani et al., 1997). On the other 
hand, variable frequencies of pl6 promoter hypermethylation was found, which 
ranged from 0 % to 40 % of childhood ALL cases (Wong et al.，2000; Yang et al.， 
2006). 
The downstream effector of p73 and p53, called p21, is another CDK inhibitor 
demonstrated promoter hypermethylation in 39 % (27 out of 68) of childhood ALL 
patients, since then, hypermethylation of p21 was conferred to a decrease of mRNA 
expression in patient samples. Multivariate analysis of potential prognostic factors 
revealed p21 methylation status as an independent prognostic factor in predicting DFS 
of childhood ALL patients (p=0.0001) (Roman-Gomez et al, 2002). 
p73 is involved in the regulation of cell cycle, cell death, cell development, 
carcinogenesis and the sensitivity towards chemotherapy (Pluta et al.’ 2006). A 
multiple-genes methylation study on p73, pl5 and p57 revealed the relationship 
between p73 and poor prognosis in adult ALL. Methylation study conferred 18 % to 
20 % of childhood ALL patients with p73 promoter hypermethylation (Canalli et al., 
2005; Roman-Gomez et al.’ 2004). 
» .. 
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2.1.2. Apoptosis 
The ability of a cancer cell to increase its number is not only influenced by cell 
proliferation but also cell attrition. Apoptosis represents a major cause of this attrition, 
in other words, the inhibition of this programmed cell death may drive cancer 
development (Reed and Pellecchia, 2005). The regulation of apoptosis is fundamental 
to hematopoietic homeostasis because stem cell renewal is continuously 
counterbalanced by apoptosis (Vaux and Korsmeyer, 1999). Therefore, aberrant 
regulation of apoptosis has been associated with the development of hematological 
malignancies (McKenna and Cotter, 1997; Rinkenberger and Korsmeyer, 1997; Hetts， 
1998; Hanahan and Weinberg, 2000). 
A protein of the ASPP family, ASPPl, is responsible for encoding a protein with 
apoptotic function. Studies have shown the capability of ASPPl in increasing the 
apoptotic effect of p53 by the inducing transcription of pro-apoptotic genes (Trigiante 
and Lu, 2006). Recent report demonstrated the promoter hypermethylation of ASSPl 
in 17 % of childhood ALL patients which was associated with decreased mRNA 
expression in patients samples, also showed a reduction in DFS (p=0.006) (Agirre et 
al, 2006). 
• 
. Death-associated protein kinase 1 gene (DAPK) encodes a novel 
serine/threonine kinase which is required for gamma interferon-induced apoptosis 
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(Katzenellenbogen et al, 1999). TMSl belongs to a growing family of apoptotic 
signaling molecules, whose cleavage and activation is regulated by its own domain 
(Conway et al.，2000). DAPK and TMSl promoter hypermethylation were detected in 
10 % of childhood ALL patients (Roman-Gomez et al., 2004; Gutierrez et al,, 2003). 
In addition, the hypermethylation of DAPK was statistically lower in T lineage ALL 
(13 %) than in B-ALL (35 %) (Gutierrez et al, 2003). 
Apoptotic peptidase activating factor (Apaf-1) plays an important role in the 
induction of mitochondrial apoptotic pathway. It forms the central element of the 
multimeric apoptosome with procaspase 9 and cytochrome c. Deficiency in Apaf-1 
protein confers resistance to cytochrome-2, c-dependent apoptosis which is found in a 
variety of tumors and leukemias (Perkins et al.’ 1998). For instance, Apaf-1 promoter 
hypermethylation has been demonstrated in acute myeloid leukemia (AML), chronic 
myeloid leukemia (CML) and also ALL, suggesting it is not specific to the types of 
leukamias (Fu et al., 2003). Aberrant hypermethylation Apaf-1 of was detected in 35 
% of childhood ALL cases (Roman-Gomez et al., 2004). 
2.1.3. Tissue Invasion and Metastasis 
« 
‘ Cell-cell interaction is generally reduced in human cancers. The reduction of 
intercellular interaction allows cancer cells to disobey their original order, resulting in 
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destruction of histological structure, which is a morphological hallmark of 
malignancies (Hirohashi and Kanai et al., 2003). Reduced intercellular interaction is 
also indispensable for cancer invasion and metastasis. The capacity of invasion and 
metastasis in solid tumors enables cancer cells to escape the primary tumor mass, 
invades adjacent tissues and travels to distant sites where nutrient and space are not 
limiting. This migratory capability causes 90 % of human cancer death (Hirohashi and 
Kanai, 2003). 
Promoter hypermethylation of two cadherin family members genes, E-cadherin 
and H-cadherin, have been observed in various cancers as well as in childhood ALL 
(Kim et al,’ 2005). The occurrence of aberrant methylation for the two genes were 
both 32 %, since then, a strong correlation of the methylation status between two 
genes was confirmed (Roman-Gomez et al.’ 2004). 
Estrogen is known as a negative regulator of normal hematopoiesis. Estrogen 
receptor gene (ER) is frequently altered in human hematopoietic malignancies (Issa et 
al., 1997). It has been shown that ER has growth and metastatic suppressor activity in 
many different cell types including breast, ovarian, prostate endometrial and 
colorectal cancer (Deroo and Korach, 2006). Also, it is aberrantly hypermethylated in 
« 
,86 % of human hematopoietic malignancies, including 8 out of 9 childhood ALL 
cases (Issa et al., 1996). 
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2.1.4. Transcription Factors andMetabolic Enzymes 
Interleukin-12 (IL-12) is an important cytokine that is important in the regulation 
of innate resistance and adaptive immunity (Trinchieri, 2003). This cytokine is 
produced by antigen-presenting cells, T-cells, N K cells and B-cells. Silencing of the 
Interleukin-12 receptor 2 gene (IL-12R2) provides growth advantage to malignant 
cells, where this is a consistent feature in pro-B, early pre-B, and pre-B childhood 
ALL. Loss of IL-12R2 m R N A expression has been shown to associate with promoter 
hypermethylation, which occur in 100 % of childhood B-lineage A L L (Airoldi I et al.， 
2006). 
CALCl is a metabolic enzyme and is generally not considered as a factor of 
tumorigenesis (Leegwater et al, 1997). On contrary, CALCl hypermethylation was 
conferred in 39 % (25 out of 49) childhood A L L patients and multivariate statistical 
analysis confirmed hypermethylation of CALCl was associated with shorter DFS {p< 
0.00001) (Roman-Gomez J et al, 2003). 
2.L5. Putative Tumor Suppressor Genes 
Phosphatase and tensin homolog gene {PTEN) is an important tumor suppressor 
I 
.which is contributes to cell adhesion, apoptosis, angiogenesis, G1 cell cycle regulation 
and signal transduction in the pathogenesis of a number of familial and sporadic 
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cancers (Zysman, 2003). Study has demonstrated the occurrence of PTEN promoter 
hypermethylation in 20 % of childhood A L L cases (Roman-Gomez J et al.’ 2004). 
NESl is a putative tumor suppressor gene located in chromosomal region 
19ql3.3-4. The NESl gene was identified by virtue of its down-regulation in breast 
cancer cell lines, and is considered to be involved in the regulation of normal cell 
growth (Roman-Gomez J et al, 2004). However, the precise physiological function of 
NESl protein is still unclear. Methylation of the NESl has been found in 39 % of 
childhood A L L cases. Moreover, down-regulation of m R N A expression has also been 
observed. Patients with methylation of the NESl had a poorer DFS than unmethylated 
patients as implied from multivariate analysis revealing shorter DFS (p=0.005) in 
those patients (Roman-Gomez J et al, 2004). 
The human homolog of the drosophila warts tumor suppressor gene, LATSl, is 
responsible to encode a novel serine/threonine kinase and functions as a component of 
the mitotic apparatus (Bothos et al., 2005). LATSl promoter hypermethylation was 
observed in 30 % of childhood A L L patients. This aberrant methylation was 
associated with decreased m R N A transcript in patient samples. Also, a decrease of 
DFS (p=0.0005) and OS (p=0.0003) were found in pediatric patients with A L L having 
.LATSl promoter hypermethylation (Jimenez-Velasco et al.’ 2004). 
‘ Dickkopfs-3 gene {Dkk-3) is a newly characterized mortalization-related gene 
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and an antagonist of the Wnt oncogenic signaling pathway, whose expression is 
decreased in a variety of cancer cell lines suggesting its role in tumorigenesis 
(Roman-Gomez J et al.，2003). Dkk-3 methylation was detected in 32 % of childhood 
A L L cases by a later study, in which, however, decrease of Dkk-3 m R N A expression 
was observed simultaneously (Roman-Gomez J et al., 2004). 
Parkin is associated with autosomal recessive juvenile Parkinsonism. Functional 
analysis has shown the contribution of parkin activity in E3 ubiquitin ligase (Cesari R 
et al, 2003). The promoter hypermethylation of Parkin was found to represent 30 % 
of the childhood A L L cases (Roman-Gomez J et al, 2004). 
2.1.6. Chromosome Instability 
A growing number of genes involved in sensing and repairing D N A damage, or 
genes involved in assuring the correct chromosomal segregation during mitosis, have 
been found to be inactivated in different cancers (Lengauer et al” 1998). Their loss of 
function causes genome instability, leading to the generation of tumor cells. 
The human fragile histidine triad gene (FHIT) is a putative tumor suppressor 
gene located at chromosome region 3pl4.2. It spans the most inducible human 
.common fragile site, FRA3B (Stam et al, 2006). FHIT protein was conferred to 
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induce apoptosis and retard turnor cell proliferation in both in vitro and in vivo studies 
(Dumon et al., 2005). Among leukemias, hypermethylation of FHIT was strongly 
correlated with ALL histology (p = 0.008), high hyperdiploid (p < 0.0001) and 
translocation-negative (p < 0.0001) categories (Zheng et al., 2003). Besides, 
hypermethylation of FHIT was found in 27.4 % (52 out of 190) of BM samples from 
childhood leukemias patients. FHIT mRNA and protein expression were found to be 
down-regulated in patients samples synchronously. Specifically, methylation study on 
childhood ALL cases revealed FHIT promoter hypermethylation was observed in 32 
% of childhood ALL cases (Zheng et al., 2003). 
Human neuronatin gene (NNAT) was mapped to chromosome reglon 
20q 11.2-q 12 and this region often exhibits loss of heterozygosity in hematological 
malignancies (MacGrogan et al., 2001). The study on the methylation status of NNAT 
gene in childhood ALL showed 69 % of promoter hypermethylation and aberrant 
methylation was associated with the decrease of mRNA transcript in patient samples 
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2.2. Methodologies in DNA Methylation Analysis 
D N A methylation status of various genes have been investigated in childhood 
ALL (Table 2.1). These studies, however, were based on prior knowledge of target 
genes previously found to be aberrantly methylated in other types of cancers. Such 
investigations have implicated the hypothesis: hematological malignancies are arisen 
through leukemic-specific promoter hypermethylation. Hence, genome-wide 
screening of D N A methylation pattern was introduced. This platform includes 
restriction landmark genomic scanning (RLGS) (Kawai et al, 1993)， 
methylation-sensitive representational difference analysis (MS-RDA) (Ushijima et al, 
1997), methylation-sensitive restriction fingerprinting (MS-RF) (Davies, 2002)， 
demethylating agent c D N A microarray (Suzuki et al, 2002) and methylation-sensitive 
arbitrarily primed P G R (MS-AP PGR) (Gonzalgo et al, 1997). 
2.2.1. Principle of Methylation-sensitive Arbitrarily Primed PCR (MS-AP PCR) 
MS-AP PCR, like other genome-wide screening techniques, has the advantage of 
requiring no prior knowledge of sequences of candidate genes so that it allows the 
investigation of genes other than those known or well characterized genes. It was 
« 
.developed at 1997 by a U S research group (Gonzalgo et al., 1997). 
‘ The principle of MS-AP P C R is illustrated in Figure 2.1. Restriction enzymes 
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commonly used in the MS-AP PGR are: Rsal, Hpall and MspL Rsal is used to 
generate small-sized D N A fragment from genomic D N A before the digestion by 
methylation sensitive or insensitive restriction enzymes. Hpall and Mspl both 
recognize the same 5'-CCGG-3' sequence. However, Hpall is methylation-sensitive 
restriction enzyme which only digests unmethylated sequence. Mspl, on the other 
hand, is a methylation-insensitive restriction enzyme which digests both the 
methylated and unmethylated sequences. Mspl digestion panel serves as an internal 
control to examine whether the D N A fragment observed under H panel is purely due 
to cytosine methylation of 5'-CCGG-3' sequence. After restriction digestion, 
arbitrarily primed P C R are done on digested D N A fragments by priming with 
arbitrary C G rich primers. These primers preferentially bind to CG-rich sequences in 
the genome. 
The resulting P C R products are then analyzed by high resolution polyacrylamide 
gel. The P C R products are selected for further analysis when bands are observed 
under R panel but not under M panel. There are four possible valid D N A methylation 
patterns generated by the MS-AP PCR (Figure 2.2) and the corresponding gel band is 
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Figure 2. 1 A schematic diagram showing the principle of MS-AP PCR. 
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2.2.2. Combined Bisulfite Restriction Analysis (COBRA) 
Combined bisulfite restriction analysis (COBRA) is a sensitive analysis to 
determine the D N A methylation status at specific gene loci by using small amount of 
starting genomic D N A (Xiong and Laird, 1997). When compared to other commonly 
used methods, such as methylation-specific PCR (MS-PCR), C O B R A has the 
advantage of being quantitative in nature. Moreover, C O B R A satisfies the three 
essential criteria for large scale studies: (1) quantitative accuracy, (2) compatibility 
with paraffin embedded tissue section and (3) Applicable to large number of samples 
(Xiong and Laird, 1997). 
Bisulfite treatment is a D N A modification technique converting immethylated 
cytosine residues into thymine residues. In contrast, methylated cytosine remains 
unchanged. The principle of C O B R A is based on the properties of methylation 
sensitive enzymes that preferentially cut modified D N A which are methylated rather 
than unmethylated (Sadri and Homsby, 1996). This sequence change leads to the 
creation of restriction sites for methylation sensitive restriction enzyme such as BstUI 
(Frommer et al.’ 1992) (Figure 2.3). The design of C O B R A primers should not 
contain C G dinucleotides; otherwise, there will be discrimination between templates 
.with different methylation status. After P C R reaction, the products will contain mixed 
、populations of methylated and unmethylated alleles. Therefore, restriction digestion 
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by methylation-sensitive restriction enzymes can directly reflect the methylation 
percentage in the original genomic D N A . The level of methylation at specific loci can 
be estimated from the relative intensity of the methylated and unmethylated band. 
Figure 2. 3 A schematic diagram presenting the principle of COBRA. 
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2.2.3. Cloned Bisulfite Sequencing 
Cloned bisulfite sequencing is a gene specific methylation analysis based on 
sequencing of P C R product amplified from bisulfite treated genomic D N A (Frommer 
et al.，1992). It provides information on the methylation status of every cytosine 
residue within the target sequence. PCR products amplified by methylation primers 
are cloned into a plasmid vector followed by sequence analysis of a number of 
individual clones. The presence of cytosine in the sequence indicates the presence of a 
methylated cytosine, whereas the presence of thymine reflects the presence of an 
unmethylated cytosine. 
2.2 4. Experimental Use of Demethylating Agents 
Two azanucleosides (5-aza-cytidine and 5-aza-2‘deoxycytidine [5-aza-dCR]) 
synthesized in 1964 were developed for cytostatic treatment primarily for acute 
leukemias (Figure 2.4). Later, it was found that these azanucleosides have the potency 
to act as a demethylating agent (Wolffe et al., 1999). 
Azanucleosides are analogues of cytosine with methyltransferase binding 
capacity. It covalently attaches to DNA-methyltransferases (DNMTs) and hence 
» . . 
.inhibits its activity (Figure 2.5) (Claus and Lubbert, 2003). Therefore, the methylation 
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of the newly synthesized D N A is prohibited and the methylated alleles are 
sequentially reduced for every D N A replication cycle, and finally lead to global 
demethylation (Michalowsky and Jones, 2003) (Figure 2.5). 
Currently, the clinical trials of azanucleosides have been assessed in solid and 
hematological malignancies (Luebbert, 2000). It has been demonstrated that 
azanucleosides is able to inhibit growth of human tumor both in in vitro and in vivo 
studies. For instance, the drug efficacy of azanucleosides has been clinically studied 
in several myeloid neoplasias in older patients, like myelodysplasia and acute myeloid 
leukemia (AML) (Ruter et al., 2004). 
Figure 2. 4 Chemical structures of Azanucleosides. 
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Figure 2. 5 Demethylating action of azanucleosides. 
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3.1. Current Methylation Studies in Childhood ALL 
Acute lymphoblastic leukemia (ALL) is a cancer of the hematopoietic system 
involving the malignant transformation of lymphoid progenitor cells which accounts 
for 30 o/o of childhood cancer (Carroll et al.’ 2003). Dramatic advances in treatment 
strategy over the past few decades have increased the childhood A L L cure rate at 
nearly 80 % (Pui et al., 1998). Although A L L is the most curable malignant diseases 
in children, its underlying genetic mechanism of A L L tumorigenesis remain largely 
unclear. 
A L L has traditionally been viewed as a genetic disease, like most other 
cancers, is caused by progressive accumulation of malignant cells with altered gene 
functions. This epigenetic modification has been associated with gene silencing, 
malignant transformation and aging (Das and Singal, 2004). Aberrant promoter 
hypermethylation of CpG island is one of the epigenetic modifications of gene 
expression in hematological malignancies (Takahashi et al.’ 2004). Through 
multi-step A L L tumorigenesis, cancer-related gene can be silenced or activated by 
D N A methylation. Nevertheless, the epigenetic profile of childhood A L L has not been 
fully studied. To date, around 100 papers have reported methylation changes in ALL, 
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which, however, only 40 of them focused on childhood ALL. Specifically, part of 
these studies focused on relapse cases rather than cases at first diagnosis and around 
20 genes were investigated in childhood ALL. In addition, only few of them have 
demonstrated a correlation between aberrant methylation with down-regulation of the 
cancer-related genes and also the disease prognosis (Table 2.1). Many of these 
methylation studies targeted on investigating specific single-gene or multiple-genes as 
a profiling study. These investigations require prior information on the D N A 
sequence, which, however, limited the current studies to known genes or 
cancer-related genes that have been reported. 
Researchers have also investigated the contribution of multiple-genes 
methylation profile in related to childhood ALL prognosis (Iravani et al., 1997; 
Roman-Gomez et ah, 2004; Gutierrez et al, 2003; Garcia-Manero et al, 2002). These 
approaches select target genes that are known to play an important role in tumor 
suppression, cell cycle regulation, apoptosis, D N A repair or metastatic potential. 
Conversely, the use of genome-wide scanning approach can allow the discovery of 
novel candidate genes because it assesses the methylation pattern with no prior D N A 
sequence information and thus allow the identification of novel genes implicated in 
< 
• childhood ALL tumorigenesis. 
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3.2. Objectives of Research 
To the best of our knowledge, this is the first genome-wide D N A methylation 
screening in A L L and childhood cancer. The objective of this study was to identify 
novel cancer-related genes in childhood ALL by first searching for CpG islands with 
leukemia-associated D N A methylation pattern using a genome-wide scanning 
approach, the MS-AP P C R and second by examining the role of promoter methylation 
in transcriptional silencing and involvement of the selected gene candidate found in 
both cell lines and clinical samples. 
MS-AP P C R is a simple and reproducible method that has been used to identify 
novel cancer-related genes in tumors. For instance, this screening strategy has been 
employed to identify novel genes that are hypermethylated in various cancers 
including colon cancer, bladder cancer, pituitary adenomas and head and neck 
squamous cell carcinoma (Liang et al, 2000; Salem et al., 2000; Bahar et al., 2004; 
Estecio et al, 2006) (will be further discussed in section 6.1). These findings 
solidified the notion that MS-AP P C R is a feasible genome-wide methylation 
screening approach to identify novel cancer related genes. Consequently, the 
clinico-patholgical contribution of the methylation regulating candidate-gene(s) can 
、be examined in childhood ALL. The identification of differentially methylated genes 
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may indicate specific molecular pathways and contribute to the prediction of 
prognosis in childhood A L L and finally help to improve therapeutic strategies in 
future. 
3.3. Study Approach and Experimental Design 
In this study, we employed MS-AP PCR as our platform to identify differential 
methylated D N A fragments from human genome using clinical samples from 
childhood A L L patients and normal healthy donors. Figure 3.1 summarized the 
experimental design of our study. The identities of target fragments identified from 
MS-AP PCR were then analyzed by D N A sequencing. B L A T analysis was done for 
each fragment to identify the presence of CpG island and to map the sequence to any 
known or novel genes. Methylation status of the 5' CpG island and m R N A expression 
of candidate genes were investigated by C O B R A , cloned bisulfite sequencing and 
semi-quantitative RT-PCR respectively. Data from demethylation studies further 
elucidated the relationship between promoter hypermethylation and transcriptional 
silencing of gene. Finally, the involvement of aberrantly methylated gene was 
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4.1. Clinical Samples and ALL Cell Lines 
4.1.1. Clinical Samples from Pediatric Patients with ALL and Normal Healthy 
Donors 
Bone marrow (BM) aspirates and peripheral blood (PB) from pediatric patients 
with A L L were obtained from the Prince of Wales Hospital. Non-malignant B M 
aspirates and PB from healthy donors were used as control. Mononuclear cells (MC) 
from these clinical samples were freshly extracted (illustrated at section 4.2.1) and 
then stored at -80 °C 
4.1.2. ALL Cell Lines 
Five A L L cell lines [697 (DMSZ), CCRF-CEM (ATCC), MOLT-3 (ATCC)， 
R E H (ATCC) and Rs4;ll (ATCC)] were obtained from the A T C C (American Type 
Culture Collection, Manassas, VA, USA) and D M S Z (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen G m b H , Braunschweig, Germany). The origins of 
these cell lines were listed in Table 4.1. The cell lines were cultured in RPMI 1640 
« 
medium (Sigma-Aldrich, St Louis, M O ) supplemented with 20 % fetal bovine serum 
(FBS), 1 % L-glutamine, 1 % penicillin/streptomyhcin (Invitrogen, Carlsbad, CA, 
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USA) and incubated in 5 % CO2 at 37。C. 
Table 4.1 Origins of ALL cell-lines. 
Cell lines Origins 
697 Human B-cell precursor leukemia 
CCRF-CEM Human T-cell leukemia 
M O L T S Human T-cell leukemia 
R E H Human B-cell precursor leukemia 
Rs4; 11 Human B-cell precursor leukemia 
4.2. Genomic DNA Isolation from Clinical Samples and Cell Lines 
4.2.1. Ficoll Gradient Centrifugation 
M C from B M and PB were isolated using Ficoll-Paque"^ ^ PLUS (Amersham 
Biosciences, Piscataway, NJ, USA). Briefly, the samples were diluted with IX 
phosphate buffer saline (PBS) and layered gently onto an equal volume of 
F i c o l l - P a q u e T M PLUS. After non-braking centrifugation at 1400 rpm for 30 minutes 
(mins), mononuclear cells were collected at the interphase layer and then washed 
twice with IX PBS. The cells were stored at -80 °C. 
4.2.2. DNA Extraction 
« 
B M M C , P B M C and cultured cell lines were digested with 3 ml saline 
Tris-ethylenediamine tetraacetic acetic (Tris-EDTA) buffer containing 5 % sodium 
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dodecyl sulfate (SDS), 0.2 mg/ml proteinase K and incubated overnight at 50。C. 
After overnight protein digestion, equal volume of phenol/ chloroform/ isoamyl 
alcohol (25:24:1) (Amersham Biosciences) was added to the mixture and then shaken 
gently for 20 mins. After centrifugation at 3500 rpm for 30 mins, the upper aqueous 
layer was collected. D N A was precipitated by the addition of 1/10 volumes of 3 M 
sodium acetate (pH 5.2) followed by 2.2 volumes of cold 100 % ethanol (BDH Inc., 
Toronto, US). After overnight precipitation at -20 °C，the mixture was centrifuged at 
3500 rpm for 30 mins at 4 °C and washed twice with cold 70 % ethanol. The D N A 
pellet was air dried and dissolved in sterilized water. The quality and quantity of D N A 
were determined by measuring the absorbance at 260/280 nm using 
spectrophotometer. The extracted D N A was stored at -20 °C. 
4.3. MS-AP PCR 
4.3.1. Methylation-sensitive Restriction Enzyme Digestion of Genomic DNA 
Totally, 8 B M M C D N A from pediatric patients with A L L were used in MS-AP 
PCR and 4 P B M C D N A from normal healthy donors were recruited correspondingly. 
The methylation-sensitive restriction digestion was carried out using 1 |ig of D N A 
.from clinical samples as shown in Table 4.2. B M M C and P B M C D N A were digested 
‘in a total volume of 20 \i\ with different panels of restriction enzymes (Rsal, Hpall, 
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Mspl) according to Table 4.3. Fifteen units of each restriction enzyme was used and 
the sample were incubated for 16 hours (hrs) at 37°C. All restriction enzymes were 
purchased from N e w England Biolabs (NEB, Beverly, M A , USA). 
Table 4. 2 Samples used in MS-AP PCR. 
Group lypes of sample used Numbers of sample used 
r, , ‘ common A L L 2 
Patient 




P B M C D N A from normal healthy donors - 4 
group 
Table 4. 3 Panels of methylation-sensitive restriction digestion. 
Panel R Panel H Panel M 
Combination of 
. . Rsal Rsal and Hpall Rsal and Mspl 
restriction enzymes 
4.3.2. Arbitrarily Primed Polymerase Chain Reaction 
The arbitrarily primed polymerase chain reaction (AP-PCR) was performed 
according to the methodology published by Maskl et al.’ 2001. D N A digests were 
amplified with 13 primer sets, each with a combination of 2 to 3 arbitrary GC-rich 
primers (Table 4.4 and 4.5). 
P C R reactions were performed with 50 ng D N A , GeneAmp IX Buffer II 
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(Applied Biosystems, Foster City, CA, USA), 1.5 m M M g C h (Applied Biosystems), 
200 |jM dNTP (Amersham Bioscience), 10 pmol of each primers, 0.5 unit of 
AmpliTaq Gold D N A polymerase (Applied Biosystems) and 4 [xCi of a ^ P^-labeled 
dATP (Perkin Elmer, Foster City, CA, USA) in a final volume of 10 nl. 
The reaction mixtures were then subjected to 95 °C hot start for 10 mins， 
followed by 42 cycles of amplification (94 °C, 2 mins; 40 °C, 1 min ； 72 °C, 2 mins) 
with a final extension at 72 °C for 10 mins. 
The P C R products were mixed with equal volume of formamide dye buffer 
[95 % formamide, 20 m M E D T A (pH 8.0)，10 m M NaOH, 0.05 % bromphenol blue 
and 0.05 % xylene cyanol], denatured at 9 5� C and then cooled immediately on ice. 
Samples (2.5 jil) were resolved on 5 % 7.5 M urea denaturing polyacrylamide gel for 
90 mins at constant voltage of 1700 V, 300 m A and 110 W . After electrophoresis, the 
gel was dried at 80 °C for 3 hrs and exposed to BioMax M R autoradiographic film 
(Eastman Kodak Company, NY, USA) with an intensifying screen at -80°C overnight. 
t 
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Table 4. 4 Primer Sequences for MS-AP PCR. 
Primer Primer sequences 
G1 5'-GCG C C G A C G T-3' 
G2 5'-CGG G A C G C G A-3' 
« 5'-CCG C G A T C G C-3' 
G4 5,-TGG C C G C C G A-3' 
G5 5'-TGC G A C G C C G-3, 
^ 5'-GGG C C G C G G C-3' 
^ 5'-CCC C G C G G G G-3' 
G ^ 5'-GCG C G C C G C G-3' 
G ^ 5'-GCG G G G C G G C-3, 
TIMl 5'-AGC G G C C G C G-3' 
TIM7 5'-GAG G T G C G C G-3' 
TIMIO 5'-AGG G G A C G C G-3, 
TIM 11 5'-GAG A G G C G C G-3' 
TIM12 5'-GCC C C C G C G A-3' 
TIM13 5'-CGG G G C G C G A-3' 
TIM17 5'-GGG G A C G C G A-3' 
TIMl8 5'-ACC C C A C C C G-3’ 
Table 4. 5 Primer sets for MS-AP PCR. 
Primer set number Primer combination 










: 11 G1，G4，G5 
, 12 G1，G2，G3 
13 G4，GC4，TIMIO 
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4.3.3. Isolation of Differentially Methylated DNA Fragments 
Differentially methylated D N A fragments were identified by comparing the 
pattern of the 3 restriction digestion panels. Target bands were isolated from the gel 
and placed in 1.5 ml microcentrifuge tube containing 40 sterile water. The tubes 
were incubated at 60 °C overnight to facilitate the dissolution of D N A fragment. 
Eluted D N A (1.5 |j,1) was re-amplified with the same primer set used in the 
M S AP-PCR to generate sufficient template for cloning and D N A sequencing. 
P C R re-amplification mix contained IX PCR buffer [10 m M Tris-HCL (pH 9.0), 
1.5 m M M g C b and 50 m M KCL], 200 ^iM dNTP (Amersham Biosciences), 
12.5 pmol of each primer, 5 % dimethyl sulfoxide (DMSO) and 1 unit of Taq D N A 
polymerase (Amersham Biosciences) in a total volume of 25 The reaction mixture 
was then subjected to 95 °C hot start for 2 mins, followed by 45 cycles of 
amplification (94 °C，1 mins; 4 9 � C , 45 seconds (s) ； 72。C，45 s) with a final 
extension of 72 °C for 10 mins. The PCR products were analyzed by 2 % (weight/ 
volume) agarose gel with 0.5 jag/ml ethidium bromide in 0.5X TBE buffer (44.5 m M 
Tris-base, 49 m M boric acid, 1 m M EDTA). The target P C R fragments were purified 
by the Gel Extraction Kit (Qiagen, Valencia, CA, USA) according to manufacturer's 
f 
.protocol and eluted in 30 \x\ sterile water. 
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4.4. Cloning of Differentially Methylated DNA Fragments 
4.4.1. TA Cloning 
The eluted P C R products were cloned using the TA Cloning® Kit (Invitrogen) 
according to manufacture's recommendations. The fragments were ligated with 
pCR2.1 vector (12.5 ng) in the presence of IX ligation buffer and 1 Weiss units of T4 
D N A ligase. The final reaction volume was 5 |li1 and the ligation mixtures were 
incubated at 1 4� C overnight. 
Transformation was performed by using TOP 10 competent cell and SOjil of cells 
were thawed on ice followed by the addition of 2 |xl of ligated product. After 
incubation on ice for 30 mins, the cells were heat shock at 42 °C for 30 s and then 
immediately kept on ice. S.O.C medium (250|al) was added to the cells and the vial 
was shaken horizontally at 225 rpm at 37 °C for 1 hr. Upon incubation, the cell 
mixture was spinned down at 6000 rpm for 15 s and 200 of medium was removed 
to minimize the total volume of cells suspension. The remaining cell mixture was 
resuspended and spread on LB agar plate [1 % tryptone, 0.5 % yeast extract, 1 % 
NaCl，15 % agar (pH 7.0) with 0.1 mg/ml ampicillin and 0.8 m g X-gal] and incubated 
at 37 °C overnight to allow blue/white colony selection. 
1 
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4,4.2. Screening of Positive Clones 
Eight white bacterial colonies were picked from each L B A agar plates and 
resuspended in 4 |il of sterilized water which acted as the P C R template. Cloned 
direct PCR was conducted to ensure the proper size of insert. P C R reaction was 
contained GeneAmp IX Buffer II, 1.5 m M MgCb, 200 |iM dNTP 10 pmol of each 
primer ( T7 promoter and Ml3 reverse primers) (Table 4.6) and 0.5 units of 
AmpliTaq Gold D N A polymerase in a final volume of 20 |li1. The reaction mixture 
was then subjected to 95 °C hot start for 10 mins, followed by 35 cycles of 
amplification (94 °C，2 mins; 40 °C，1 min ； 72 °C，2 mins) with a final extension of 
7 2� C for 10 mins. The P C R products were then analyzed by 2 % (w/v) agarose gel. 
Table 4. 6 Primer sequences and PCR conditions for DNA sequencing, COBRA and 
semi-quantitative RT-PCR. 
Amplicon Purpose Primer sequence 广广、 product 
( ) size (bp) 
~T7 D ^ 5'-TAATACGACTCACTATAG- 3' 50 WA 
promoter Sequencing 
M13 5 '-AGGAAAC AGCTATGACC A-3 ‘ 
reverse 
FBN2 COBRA Forward: 55 404 
5 '.TTTTTGTTTGTTTGTTTGTTTTTTTT-3 ’ 
Reverse: 
5 ’-AAAATCAAAATCTAATAAACCCTTC-3 ’ 
FBN2 Semi- Forward: ^ ^ 
quantitative 5 '-GTTGCAGGTAAAGACGTGTG-3 ’ 
RT-PCR Reverse: 
. 5 '-CTCACAGAACTCTCGGGTCC-3， 
.GAPDH Semi- Forward: ^ sn 
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4.4.3. Preparation of Plasmid DNA by Alkaline Lysis Method 
Bacterial colonies with positive clones were inoculated in 1.5 ml LB Broth 
(Amersham Biosciences) with 0.1 mg/ml ampicillin and shaken at 225 rpm for 16 hrs 
at 37 °C . Cell suspensions were centrifiiged at maximum speed for 20 s to remove 
the LB Broth. The cell pellet were resuspended in 100 \i\ G T E buffer [50 m M glucose, 
25 m M Tris-Cl (pH 8.0)，10 m M EDTA] and incubated at room temperature (RT) for 
5 mins to lyse bacterial membrane. Bacterial protein, chromosomal D N A and plasmid 
D N A were denatured by addition of 100 ^il freshly prepared 0.2 M N a O H / 1 % SDS 
solution. The mixture was inverted upside down and placed at R T for 5 mins and then 
neutralized with 150 ]x\ of 5 M potassium acetate (pH 4.8). The mixture was inverted 
upside down and placed on-ice for another 5 mins. The mixture was centrifiiged at 
maximum speed for 10 mins at 4 °C and the supernatant was collected. Plasmid 
D N A was precipitated by the addition of 2.2 volume of cold absolute ethanol and the 
pellet was washed twice by 70 % ethanol. The pellet was air dried and resuspended in 
50 \i\ sterilized water. 
4.5. DNA Sequence Analysis of Differentially Methylated DNA Fragments 
< 
.4.5.1. Dye-terminator Cycle Sequencing 
、 Dye-terminator cycle sequencing was performed on cloned target D N A 
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product by BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) 
according to the manufacture's instructions. The sequencing reaction was performed 
with 1 |ig plasmid D N A , IX Bigdye® v3.1 Sequencing Buffer, IX ready reaction 
premix and 10 pmol of Ml3 reverse primer (Table 4.6). The reaction mixture was 
then subjected to 96。C initial denaturation for 1 mins followed by 30 cycles of 
dye-termination reaction (96。C，10 s; 50。C，5 s ; 60 °C，4 s). The sequencing 
products were purified by Sephadex G-50 spin column (Amersham Biosciences). The 
purified products were mixed with an equal volume of Hi-DiTM Formamide (Applied 
Biosystems) followed by denaturation at 95 °C for 3 mins. The electrophoresis was 
performed by using ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems). 
Sequence homologies were determined using the blastn program of the National 
Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/BLAST/). 
4.5.2. CpG islands Analysis of Differentially Methylated Sequences 
The differentially methylated fragment was verified by the presence of Hpall 
restriction site. The sequences were analyzed by the Human B L A T Search provided 
< 
.from the U C S C Genome Bioinformatics Site (http://genome.ucsc.edu/). The 
‘sequences were searched against putative CpG islands, which are defined as a D N A 
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region(s) greater than 200bp with G C content higher than 0.5 and an 
observed/expected CpG ratio above 0.6 (Gardiner-Garden and Frommer, 1987). 
4.6. DNA Methylation Analysis 
4.6.1. Sodium Bisulfite Modification 
The sodium bisulfite modification of genomic D N A was performed by the EZ 
D N A modification Kit (Zymo Research, Hornby, Canada) according to 
manufacturer's instruction. Firstly, 2 |ig of genomic D N A was mixed with 5 |il of 
M-Dilution Buffer and finally adjusted to 50 |j.l by sterilized water. The mixture was 
incubated at 37 °C for 15 mins. CT Conversion Reagent is a solid chemical mixture 
and it was prepared by addition of 750 |j,l sterilized water together with 210 
M-Dilution Buffer. After 37 °C incubation, 100 \i\ of the freshly prepared CT 
Conversion Reagent was added to the mixture followed by gentle vortexing. The 
mixture was then incubated in dark at 50 °C for 16 hrs. After overnight incubation, the 
sample was incubated on ice for 10 mins. M-Binding Buffer (400 |a,l) was added to the 
mixture and the mixture was loaded into Zymo-Spin I Column. The column was 
centrifuged briefly to allow D N A collection and it was washed by 200 of M-Wash 
.Buffer, M-Desulphonation Buffer and M-Wash Buffer sequentially. Finally, the 
、modified D N A were eluted by 30 |j1 sterilized water and stored at -20 °C. 
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4.6.2. Combined Bisulfite Restriction Analysis 
C O B R A was used to determine the methylation level of specific locus. Ten 
B M M C and 10 P B M C from non-malignant donors were used as control. Besides, 5 
ALL cell lines and 64 B M M C from pediatric patients with A L L samples were use d in 
C O B R A (Table 4.7). The desired locus was amplified from bisulfite modified D N A 
with specific primers which were designed by the MethPrimer Program 
(http://www.urogene.org/methprimer/indexl.html) (Table 4.6). P C R reactions were 
performed with 3 [i\ bisulfite modified D N A template, GeneAmp IX Buffer II，1.5 
m M MgCb，200 ^iM dNTP，10 pmol of each primer and 0.5 unit of AmpliTaq Gold 
D N A polymerase in a final volume of 20 |il. The reaction mixture was then subjected 
40 cycles of amplification and the PCR conditions were shown in Table 4.6. The PCR 
products were digested with BstUI (NEB) at 60� C overnight and the products were 
resolved by non-denaturing 10 % polyacrylamide gel. The gel was stained with 
0.5 |ig/ml ethidium bromide in IX TBE buffer and visualized under U V illuminator. 
f 
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Table 4. 7 Samples used in COBRA. 
Group lypes of sample used Numbers of sample used 
697，CCRF-CEM, MOLTS, REH, 
A L L cell lines 6 
Rs4;ll 
Patient group B M M C from pediatric patients with Pro-B A L L 1 
A L L Early pre-B A L L 5 
Common A L L 35 
Pre-B A L L 17 
T-ALL 6 
Control group Non-malignant B M M C 10 
P B M C form normal healthy donors 10 
4.6.3. Cloned Bisulfite Genomic Sequencing 
The remaining un-digested P C R products amplified from bisulfite modified 
genomic D N A were cloned into the pCR2.1 vector using the T A Cloning® Kit as 
described previously in section 4.4.1. The plasmid D N A was prepared by alkaline 
lysis method as mentioned in section 4.4.3 and sequenced by ABI PRISM® 3100 
Genetic Analyzer (Applied Biosystems) to identify the methylation、status of each C G 
site among specific locus. 
4.7 Gene Expression Study 
4.7.1. RNA Extraction from Clinical Samples and ALL Cell Lines 
% 
“ Total R N A was extracted by resuspending the B M M C , P B M C and A L L cell lines 
in TRIzol® Reagent (Invitrogen). The cells were completely homogenized in 1 ml 
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TRIzol® Reagnet and then incubated for 10 mins at RT. Chloroform (200 jal) (BDH 
Inc.) was added to each sample and the mixture was shaken vigorously for 15 s. It was 
incubated for 5 mins at R T and then centrifuged at 12000 rpm for 15 mins at 4 °C. 
The upper aqueous layer was collected followed by the addition of 500 [d isopropyl 
alcohol (BDH Inc.). The mixture was mixed gently and incubated for 30 mins at -20 
°C. After incubation, the mixture was centrifuged at 12000 rpm for 20 mins at 4 °C. 
The R N A pellet was washed twice with 75 % ethanol. Finally, the pellet was air dried 
and dissolved in DEPC-treated water. D N A contaminations were eliminated by 
DNasel digestion (Amersham Biosciences). Total R N A was treated with TRIzol® 
Reagent again to remove the DNasel, the procedures were repeated once. The quality 
and quantity of R N A were determined by measuring absorbance at 260/280nin with a 
U V spectrophotometer. 
4.7,2. Reverse Transcription PCR 
One microgram of total R N A was used to synthesize first strand c D N A by using 
the M u L V reverse transcriptase (Applied Biosystems). The total reaction volume was 
20 [i\ containing 50 units of M u L V reverse transcriptase, 50 pmol random hexamer 
« 
,(Applied Biosystems), 20 units RNase inhibitor (Applied Biosystems), GeneAmp IX 
、Buffer II, 1.5 m M MgClz, 200 |aM dNTP. The conditions for synthesis were: 22 °C 
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for 25 mins, 42�C for 65 mins and 92 °C for 2 mins. 
4.7.3. Semi-quantitative RT-PCR 
In order to determine the relative expression of the target gene, semi-quantitative 
PCR was performed. Primers specific for each target genes were designed by the 
PrimerS program developed by Whitehead Institute for Biomedical Research 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 一www.cgi). Totally 27 B M M C 
samples from pediatric patients with A L L were used in semi-quantitative RT-PCR 
(Table 3.8). Briefly, 1 |li1 of the first strand c D N A was used for P C R amplification in a 
total volume of 20 |il. The reaction mixture contained IX GeneAmp Buffer II，1.5 
m M MgCl2, 200 |aM dNTP, 10 pmol of each primer (GAPDH and target genes) 
(Table 3.7) and 0.5 units of AmpliTaq Gold D N A polymerase. The reaction mixtures 
were then subjected to 95 °C hot start for 10 mins, followed by 30 cycles of 
amplification according to Table 3.7 with a final extension of 72 °C for 10 mins. The 
PCR products were then analyzed by 2 % (w/v) agarose gel. The relative expressions 
of the target gene were determined by the normalization with the housekeeping gene, 
GAPDH, which served as an internal control. 
« 
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Table 4. 8 Samples used in semi-quantitative RT-PCR. 
Group Types of sample used Numbers of sample used 
697, CCRF-CEM, M0LT3，REH, 
A L L cell lines 6 
Rs4;ll 
Patient group B M M C from pediatric patients with Early pre-B A L L 1 
A L L Common A L L 14 
Pre-B A L L 7 
T-ALL 5 
Control group P B M C form normal healthy donors 13 
4.7.4. 5-aza-2 '-deoxycytidine Demethylation Treatment 
Cells were seeded at a proper starting density as recommended by the providers 
(DMSZ and ATCC). After 2 to 3 passages of high cell viability (greater than 95 %), 
cells were seeded at a density of 1X10^ in a 25 cm^ culture flask and were treated with 
different concentration (1 |iM, 3 |iM, 5 \iM, 10 |xM) of 5-Aza-dCR (Sigma-Aldrich) 
for 4 days. The drug was replenished at 48 hrs during treatment period. At the end of 
the drug treatment, cells were collected for R N A extraction. The relative expressions 
of the target gene under different concentration of 5-Aza-dCR were determined by the 
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5.1. Generation of DNA Methylation Pattern by MS-AP PCR 
A total of 8 pediatric patients with acute lymphoblastic leukemia (ALL) (2 
common ALL, 4 pre-B A L L and 2 T-ALL) and 4 normal healthy control subjects were 
recruited for MS-AP PCR. A representative MS-AP P C R gel image showing the 
methylation patterns generated from the bone marrow (BM) and peripheral blood (PB) 
mononucleated cell (MC) samples from the patients and normal controls was 
illustrated in Figure 5.1. 
The analysis of the methylation patterns generated by MS-AP P C R was 
summarized in Figure 5.2. The selection criteria for identifying a differential 
methylation pattern were: (1) absence of band under M panel, (2) consistence of 
methylation status showed in all normal controls (i.e. either all 4 normal controls were 
methylated or unmethylated) and (3) >1 of the 8 leukemic samples showed differential 
pattern compared with the normal controls. 
« 
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Figure 5.1 (AJ A representative gel image of methylation pattern obtained from 
MS-AP PCR. 
(B) Examples of differential methylation patterns: hypermethylation and 
hypomethylation. 
Genomic D N A from clinical samples of childhood A L L B M and normal P B M C were 
digested by 3 combinations of restriction enzymes (R, H and M panels as described in 
section 4.3.1.) and were amplified by 13 combinations of arbitrary GC-rich primers. 
Hypermethylation was indicated by the positive methylation (marked by arrows) in >1 
leukemic samples, but unmethylated in all normal P B M C samples. Hypomethylation 
was indicated by the positive methylation status (marked by arrows) in all normal 
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Figure 5. 2 Flow chart demonstrating the validation of methylation patterns. 
No Invalid 
Absence of PCR product under M Panel • pattern 
' ： No Methylation 
Methylation status consistent ^ status not 
in normal control group comparable 
Yes — 
，r 
>1 leukemic sample(s) showed different No No 
methylation status compared with normal ^ differential 
control group methylation 
[ y S 
1 r 
Differential methylation 
Methylated in control Unmetnylated in 
group but control group but 
unmethylated in >1 methylated in >1 
leukemic samples ^jlggjgjj^ggjjgi^gg^g^^^ 
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5. LI. Differential Methylation Patterns of Childhood ALL 
By comparing the methylation patterns between the leukemic and normal control 
groups, 40 differentially methylated fragments were identified (Table 5.1). The total 
number of differential methylated fragments observed in the normal controls were 13 
and in clinical samples were 13 in common ALL, 22 in pre-B A L L and 18 in T-ALL 
(Table 5.1). 
Table 5.1 Comparison of the methylation patterns between childhood ALL and 
normal controls. 
Methylation status (#, methylated;〇，unmethylated) of the 40 D N A sequences in 8 
leukemic and 4 normal P B M C samples were shown. Their methylation status was 
classified as (1) hypermethylation common in B and T lineage ALL; (2) 
hypermethylation specific to B lineage ALL; (3) hypermethylation specific to T 
lineage ALL; (4) hypomethylation common in B and T lineage ALL; (5) 
hypomethylation specific to B lineage ALL; (6) hypomethylation specific to T lineage 
ALL. Percentages of methylation (% of methylation) in each sample and the total 
number of differential methylated fragments observed in each A L L subtype were 
shown at the bottom of the table. (Total no. of methylated fragments indicates the 
maximum numbers of methylated fragments found in each leukemic group.) 
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� Normal PBMC Cojiji^on Pre-B ALL T-ALL 
Seq no. ^ ^ Category 
1 2 3 4 5 6 7 8 9 10 11 12 
1 〇 o o o o o • 參 o o o o 丨 2 
2 o o o o • o • o • o“ # 參 1 
3 0 0 0 0 0 ® 0 0 • 參 G O 2 
4 o o o o o o o « o o o o 2 
5 o o o o 參 o • • 參 o c : » o 2 
6 • 參 鲁 • 參 o • 參 鲁 眷 會 o 4 — 
— 7 參 • 參 參 o 參 鲁 • • 參 參 5 — 
8 • 參 • • 0 0 0 0 0 0 0 0 4 
9 • • 參 • 0 0 0 0 0 0 0 0 4 
10 0 o o o « o o o o o 參 參 1 
n 0 0 0 0 0 0 參 參 • o » o 1 
n O 0 0 0 0 0 鲁 0 眷 0 參 o 1 
1 3 o o o o 參 鲁 參 o 參 o • c 1 
1 4 o o o o o o « o o o O Q 2 
1 5 o o o o o o ^ o 參 鲁 o 鲁 1 
o o o o o o o o 參 • < : > 參 1 
n o o o o o o o o o o • 參 3 
o o o o o o o o » o • 鲁 1 
1 9 o o o o o o o o 鲁 鲁 o • 1 
2 0 o o o o o o o o • o o o 2 
2 1 o o o o o o o ^ o * o : 2 
2 2 o o o o o o o » o o o 2 
“ 2 3 • 會 參 書 鲁 鲁 鲁 參 鲁 參 ^ c 6 
2 4 0 0 0 0 書 • 參 鲁 參 參 • • 1 
25 參 攀 • 參 o o o o 參 o o o 4 
2 6 4 
2 7 參 眷 參 參 o 參 參 鲁 • 〇 參 離 4 
“ 2 8 鲁 會 參 參 參 參 參 • 參 參 0 鲁 6 
^ • # • • 0 0 0 0 0 0 ~ * o D 4 
^ 0 0 0 0 0 0 0 0 0 0 • 參 3 
M 0 0 0 0 0 0 0 • 參 參 0 • 1 
^ 0 0 0 0 0 0 0 參 o o > c _ 1 
^ 0 o o o » o o » o o " " * " o o 2 
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“ 4 0 鲁 鲁 鲁 參 鲁 眷 參 鲁 • 參 參 • 1 
Total No. of 
methylated 13 13 22 18 
fragments 
0/0 of methylated 33 33 30 45 45 55 33 " ~ 
fragments 
Total No. of 
unmethylated 27 27 18 22 
fragments , 
‘ % of . 
unmethylated 68 68 70 55 55 45 68 55 60 
fragments 
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5.1.2. Methylation Patterns of B and T lineages Childhood ALL 
The observed methylation statuses from MS-AP P C R were further categorized 
into 6 groups: (1) hypermethylation common to both B and T lineage ALL; (2) 
hypermethylation specific to B lineage ALL; (3) hypermethylation specific to T 
lineage ALL; (4) hypomethylation common to B and T lineage ALL; (5) 
hypomethylation specific to B lineage ALL; (6) hypomethylation specific to T lineage 
ALL. Table 5.2 summarizes the methylation statuses according to B or T lineages of 
ALL. It was found that hypermethylation (70 % ) were generally more common than 
hypomethylation (30 %). Moreover, lineage specific hypermethylation were more 
prevalent with respect to B lineage (30%) than T lineage A L L (5%). In contrast, 
hypomethylation were similarly infrequent for both B lineage A L L (7.5%) and T 
lineage A L L (5%). 
Table 5. 2 Percentages of methylation statuses observed in childhood ALL. 
Characteristics % of hypermethylation % of hypomethylation 
Common to B and T 
… 35 % (14/40) 17.5 % (7/40) 
lineage A L L 
B lineage A L L only 30 % (12/40) 7.5 % (3/40) 
T lineage A L L only 5 % (2/40) 5 % (2/40) 
Total 70 o/o (28/40) 30 % (12/40) 
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5.2. UCSC BLAT Analysis of Differential Methylated DNA Sequences 
Differentially methylated D N A fragments were analyzed by D N A sequencing. To 
eliminate false positive, Hpall restriction site should be present within the D N A 
sequence. This indicated the fragments identified from the MS-AP PCR were solely 
due to differential methylation. U C S C BLAT analysis of the 40 differentially 
methylated D N A sequences (28 hypermethylated and 12 hypomethylated) revealed 25 
of the sequences showed homology to known or novel genes. Among the 25 genes, 13 
of them were adjacent to or within defined CpG island (Table 5.3). 
t 
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Table 5. 3 Characteristics of the 25 differentially methylated sequences showing 
sequence homology to known or novel genes. 
S e a n c e Corresponding Known mRNA corresponding CpG 
. island 
I ^ m o r suppressor homolog 1 / 5. end 4q35.2 
(Drosophila) 
. _ . , . * • z： / within transcribe , , ” 
5 Paired box protein 6 ^ l l p l 3 
6 Chromosome 14 open reading frame 58 overlapped with 5 14q24.3 
g Myeloid/lymphoid or mixed-lineage ^ overlapped with 5' 11 23 3 
leukemia e ^ ‘ 
9 ATP-dependent RNA helicase x - 14q32.13 一 
II TAB 1-like protein * ： 22ql3.1 
SH2 and PH domain-containing adapter ^ ~2000bp away 7 22 1 
protein APS from 5' end ^ . 
14 Hypothetical protein PSEC0266 * - 22ql3.31 
16 G protein-coupled receptor kinase 5 * - 10q26.11 
18 Ataxin 2 ( 5'end 12q24.12 
19 Fibrillin 2 precursor / overlapped with 5' 5^23.! 
“ 20 SFRS protein kinase 2 x - 7q22.3 
22 Hypothetical protein FLJ35924 * ： 18pl l .2 
23 Zinc fingers and homeoboxes protein 2 ^ overlapped with 5 12ql3 . l l 
protein tyrosine phosphatase, receptor 仔 
24 type, f polypeptide (PTPRF), interacting 乂 ~ /uuop away irom i2q21.31 
protein (liprin), alpha 2 
25 Striatin, calmodulin binding protein 4 * - 19ql3.32 
26 Sarcosine dehydrogenase * - 9q34.2 
27 Zinc finger, BED domain containing 4 / overlap^g with 5’ 22ql3.33 
28 Sushi-repeat-containing protein, X-linked � 3' end X p l l . 4 
29 Transcription factor 20 (ARl) (TCF20) x - 22ql3.2 
32 KIAA0518 protein * - 15ql5.1 
33 RAN binding protein 1 Z with 5’ 22ql l .21 
DNA (cytosine-5-)-methytransferase 3 ^ U ^^ 
beta “ 
Pleckstrin and Sec7 domain containing „ 
jiy . • - * - oDZZ 
protein 3 
Platelet-derived growth factor receptor, ^ overlapped with 5' ^ ^^ 
« 
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5.3. Identification of Candidate Gene 
All the 13 candidates identified from MS-AP P C R showed homology to 
known or novel human m R N A s sequences, 10 of them were mapped to the 5' regions 
of known or novel genes (Table 5.4). 
W e first selected candidates with CpG island(s) mapped to 5' region of a known 
or novel gene (N=10), and finally we extend our target to candidates with CpG island 
mapped to coding region (N=l) and 3' region (N=2). The m R N A expression of these 
13 known or novel genes in 5 A L L cell lines (697，CCRF-CEM, MOLTS, R E H and 
Rs4;ll) were examined by semi-quantitative RT-PCR. Among all，differential 
expression of fibrillin 2 {FBN2) m R N A was found in the A L L cell lines (N=5) 
compared with normal P B M C (N=6) (will be discussed in sections 5.4), while the 
others {FAT, PAX6, cl4orf58, MLL, APS, ATXN2, ZHX2, PPFIA2, ZBED4, SRPX2, 
RNABPl and PDGFR- a) showed no significant changes in m R N A expression 
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Table 5. 4 Thirteen putative target sequences those were adjacent to or within a 
defined CpG island. 
Differential 
Seq Differential Corresponding Gene 
Corresponding Known mRNA mRNA 
No. methylation status CpG island name 
expression 
Tumor suppressor homolog 1 
1 Hypermethylation 3’ FAT * 
(Drosophila) 
5 Hypermethylation coding region Paired box protein 6 PAX6 * 
Chromosome 14 open reading frame 
6 Hypomethylation 5' cl4orp8 * 
58 
Myeloid/lymphoid or mixed-lineage 
8 Hypomethylation 5’ MLL * 
leukemia 
SH2 and PH domain-containing 
13 Hypermethylation 5’ APS * 
adapter protein APS 
18 Hypermethylation 5’ Ataxin 2 ATXN2 * 
19 Hypermethylation 5' Fibrillin 2 precursor FBN2 ^ 
Zinc fingers and homeoboxes protein 
23 Hypomethylation 5’ ZHX2 x 
2 
Protein tyrosine phosphatase, 
24 Hypermethylation 5’ receptor type, f polypeptide (PTPRF), PPFIA2 * 
interacting protein (liprin), alpha 2 
Zinc finger, BED domain containing 
27 Hypomethylation 3’ ZBED4 * 
4 
" 2 8 H y p o m e t h y l a t i o n ； �^‘丨“丨“呂 Pr�tein’ ^ x ~ 
33 Hypermethylation 5’ RAN binding protein 1 RNABPl * 
Platelet-derived growth factor 
40 Hypermethylation 5’ PDGFR- a x 
receptor, alpha polypeptide 
5.4. FibrUlin 2 
5.4.1. FBN2 CpG Islands: UCSC BLAT Search Analysis 
, U C S C BLAT analysis indicated that a CpG island was localized in the putative 
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promoter region of the FBN2 (Figure 5.3). This CpG island sizes about 2382 bp in 
size and has a G C content of 59 % and an observed / expected CpG ratio of 0.90. 
Figure 5.3 UCSC BLAT analysis ofFBN2. 
As shown in the graph, G C percentage indicates the content of C G dinucleotides. 
Black rectangle indicates the location of the differentially methylated sequence 
identified. Blue rectangle indicates the location of the FBN2 gene, and green rectangle 
indicates the CpG island. 
cnrs： 127901 •9e| 1279«29»9| 1279M …| 127995"»| Your S»<wnc» fro» Bint S*iircn 
vourseq Bimi 
o»r>*s 
PBN2 — i m — — CpC Itliwxis (I»l»n0i < B»s»« *r* Light Cr*f\) 
5.4.2. Verification of FBN2 by ALL Cell Lines 
5.4.2.1. Semi-quantitative RT-PCR 
Semi-quantitative RT-PCR analysis of FBN2 m R N A expression in 5 A L L cell 
lines and 6 normal P B M C samples were shown in Figure 5.4. Loss of expression of 
FBN2 m R N A was detected in Rs4;ll, CCRF-CEM and M 0 L T 3 while reduced 
expression was observed in 697. In contrast, FBN2 m R N A showed comparable level 
in R E H as compared with the normal P B M C samples. 
« 
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Figure 5. 4 Semi-quantitative RT-PCR of FBN2 mRNA expression in 5 ALL cell 
lines and 6 normal PBMC samples. 
FBN2 m R N A expression was silenced in Rs4;ll, CCRF-CEM and M 0 L T 3 but 
down-regulated in 697. Amplification of GAPDH c D N A was performed as an internal 
control for R N A integrity. 
B lineage ALL T lineage ALL Normal PBMC 
C C R F - … … P B M C PBMC PBMC PBMC PBMC PBMC 
REH 697 Rs4;l l CEM MOLT3 | 2 3 4 5 6 
FBN2 mijiiiiiiiiiiiiiiiiiniiiiiiimiiiiniiiiiiiiiiiiiiii^^^niiiii^ 
GAPDH iniiiiimiiiiniiiiiiiiiimiiiiiiiiimmiiiiiiiiiim 
5.4.2.2. C O B R A 
C O B R A was performed to evaluate the methylation status of FBN2 promoter in 
5 A L L cell lines, 10 B M M C samples from non-malignant subjects and 10 normal 
P B M C samples from normal healthy donors. The PCR product was designed to span 
from nucleotide -479 to -76 of the FBN2 putative promoter region. This region 
contained 39 C G dinucleotides and 3 BstUI restriction sites (Figure 5.5). All the 
non-malignant B M M C and normal P B M C samples were unmethylated as no 
methylated bands were observed (Figure 5.6B). As shown in Figure 5.6A, 2 
methylated bands, were detected in R E H while 3 methylated bands were detected in 
Rs4;ll, 697, CCRF-CEM and M0LT3, this indicated FBN2 promoter 
hypermethylation occurred at different BstUI sites in all the 5 A L L cell lines (Figure 
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5.5A). An unmethylated band was observed in R E H and we defined R E H had a partial 
methylation (PM) while the other 4 A L L cell lines had no unmethylated band and 
their methylation status were defined as full methylation (FM). Demonstrated by 
C O B R A , the relative methylation density in R E H cell line was comparatively lower 
than other 4 A L L cell lines. This result was concordant with the m R N A expression 
results because the FBN2 m R N A expression was found to be loss or down-regulated 
in those 4 A L L cell lines with higher methylation density as defined by C O B R A . 
Figure 5. 5 A schematic diagram showing the primer design of COBRA and the 
position of BstUI cut sites in the FBN2 putative promoter region. 
The location of C G dinucleotides {vertical red lines) is indicated within the CpG 
island. The first nucleotide of exon 1 is marked with a bent arrow and assigned as +1. 
The region analyzed by C O B R A and bisulfite sequencing spans from -479 to -76. 
Cleavage of the P C R product (404 bp) with BstUI yielded various bands (249 bp, 107 
bp, 36 bp and 12 bp) 
+1 
^ Priming ^ 
CpG island region 
/ y U J i f l II I _ I I II 丨 M l l l l CiBI I ill I III! I l l | | U _ i L l _ J - - l l | y E x o n / / 
-4T9 -76 
IIIP^RR productim^^ 
• ^ •^：：：：：：；：；…： 
she ‘~• I I 丨息‘―‘~‘丨•‘^~•—JI I •LJ_LJ_I1—1_I 1 I««I—I_I I I I~I1—1~1—1 
t t t 
‘ 249bp lOTbp "12bp* • 36bp 
t BMC//cutting Site 
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Figure 5. 6 COBRA analysis of the FBN2 putative promoter region in 5 ALL cell 
lines. 
This gel picture shows the methylation status of the FBN2 promoter region in 5 A L L 
cell lines, 10 B M M C non-malignant and 10 normal P B M C samples. Unmethylated 
and methylated bands were indicated by arrows. The methylation status of each 
sample was indicated in the figure. 
(Key: U\ unmethylated; M\ methylated; FM\ flill methylation; PM\ partial methylation; 
U\ unmethylated). 
(A) B lineage ALL T lineage ALL 
CCRF-
REH 697 Rs4;ll CEM M0LT3 
PM FM FM FM FM Methylation 
• status 
— Unmethylated (404bp) 
Methylated band (107+36bp) 
y Methylated 
( B ) Control 
Non-malignant BMMC Normal PBMC 
I 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
« 
» 
5.4.2.3. Cloned Bisulfite Sequencing 
To determine the methylation density of FBN2 putative promoter region, cloned 
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bisulfite sequencing was performed for 5 ALL cell lines, 2 B M M C samples from 
non-malignant subjects and 2 P B M C samples from normal healthy donors. Figure 5.7 
showed that all the P C R clones analyzed were heavily methylated in the 4 F M cell 
lines, which had an overall methylation level of 97.9 % (697)，98.5 % (Rs4;ll)， 
96.4% (CCRF-CEM) and 93.8 % (MOLTS) respectively. The methylation level of 
FBN2 in R E H was only 18.5 % . This low frequency of methylated CpG sites in R E H 
was concordant with the semi-quantitative RT-PCR and C O B R A results. Compare 
with our non-malignant B M M C and normal P B M C , the methylation frequencies were 
obviously lower than A L L cell lines. 
Figure 5. 7 Cloned bisulfite sequencing of FBN2 putative promoter in 5 ALL cell 
lines. 
Each row of squares represents 1 P C R clone, and each square represents a CpG site. 
The methylation status defined by C O B R A and the overall methylation level of the 
FBN2 promoter in each sample was shown in the right column. 
(A) Five P C R clones from 5 A L L cell lines (REH, 697，Rs4;ll, CCRF-CEM, M0LT3) 
(B) Five P C R clones from 2 non-malignant B M M C and 2 nonnal P B M C samples 
were sequenced. 
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5.4.2.4. Demethylation Treatment Resorted FBN2 m R N A Expression in A L L Cell 
Lines 
To confirm the role of FBN2 promoter hypermethylation in the control of 
FBN2 m R N A expression, FBN2 m R N A non-expressing cell lines CCRP-CEM, 
MOLTS, Rs4;ll and down-regulated cell line 697 were treated with various 
concentrations of 5-aza-2'-deoxycytidine (5-Aza-dCR) for 96 hours. Figure 5.8 
showed that demethylating agent induced a dose-dependent increase of FBN2 m R N A 
levels in those cell lines. Conversely, no significant change in GAPDH expression was 
observed. These data further indicated that methylation of the FBN2 promoter 
inactivated its expression in A L L cell lines. 
« 
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Figure 5. 8 Reactivation of FBN2 mRNA expression by 5-Aza-dCR. 
The non-expressing (CCRF-CEM, M0LT3, Rs4;ll) or down-regulating (697) cell 
lines were treated with various concentrations (1,3, 5 and 10 |aM) of 5-Aza-dCR for 
96 hours. Total R N A was extracted from untreated and treated cells for 
semi-quantitative RT-PCR analysis. FBN2 m R N A expression was dose-dependently 
restored after 5-Aza-dCR treatment. Amplification of GAPDH c D N A was carried out 
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5.4. S. Studies ofFBNl in Childhood ALL 
5.4.3.1. Methylation Analysis 
The contribution of FBN2 promoter hypermethylation was validated in A L L cell 
lines by semi-quantitative RT-PCR, C O B R A and cloned bisulfite sequencing. W e next 
« 
.examined whether hypermethylation of the FBN2 promoter could be detected in 
B M M C samples from pediatric patients with ALL. W e used C O B R A to evaluate 
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FBN2 promoter hypermethylation in 64 leukemic samples (Figure 5.9). The results 
showed that 69 % (44 out of 64) patients had FBN2 promoter hypermethylation. The 
methylation frequency of A L L subtypes was summarized in Table 5.5. In addition, 
statistical analysis revealed FBN2 promoter hypermethylation was common for both 
B and T lineage A L L (^=0.1649, >0.05, N=64 by Fisher's exact test). On the other 
hand, the methylation frequency in B lineage A L L subtypes showed no significant 
differences (p=0.307, >0.05, N=58 by Pearson chi-square test). These data indicated 
the FBN2 promoter hypermethylation was not specific to cell lineages (B or T 
lineages) and B lineage subtypes (pro-B ALL, early pre-B ALL, common A L L and 
pre-B ALL) and thus is a common event in childhood ALL. 
Promoter hypermethylation status provides important information for disease 
prognosis. However, statistical analysis on the FBN2 methylation status showed no 
correlation with clinical risk groups as indicated by the chi-square test (p=0.092, 
>0.05, N=44). 
Aberrant expression of myeloid markers C D 13 and CD33 were observed in 42 
among 64 patients in our clinical samples. W e next examined the correlation between 
methylation status of FBN2 and the aberrant expression of myeloid markers. The 
、chi-square test result was significant (p=0.043, <0.05, N=38, by t-test) and we can 
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conclude that there is significant difference in the means of C D 13 expression between 
promoter hypermethylation of FBN2 patient at 5 % level of significance. 
In order to validate FBN2 methylation status with the progression of childhood 
A L L (further discussion can be found in section 6.5.3), statistical analysis was done to 
examine the correlation between FBN2 methylation status with the white blood cell 
count (WBC) (N=59) and PB blast (N=59). However, no correlation was found 
between them. 
To further evaluate the methylation status of each CpG sites, cloned bisulfite 
sequencing was performed on 4 B M M C from pediatric patients with ALL. Our data 
showed that varying degrees of methylation (29% to 87 % ) were detected in these 
patients with FBN2 promoter hypermethylation. In addition, all the clones from the 
two patients with no FBN2 promoter hypermethylation showed clear immethylation 
patterns (Figure 5.10). These data confirmed the presence of FBN2 promoter 
hypermethylation in pediatric patients with ALL. 
« 
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Table 5. 5 Methylation frequency of childhood ALL lineages and subtypes. 
Types of Childhood A L L Methylation frequency (%) 
ALL 69 o/o (44/64) 
B lineage A L L 66 %(38/58) 
Pro-B A L L 100% (1/1) 
Early Pre-B A L L 100 % (5/5) 
Common A L L 63 % (22/35) 
Pre-B A L L 59%(10/17) 
T lineage A L L 100 %(6/6) 
% 
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Figure 5. 9 A representative gel image of COBRA of FBN2 putative promoter in 
childhood ALL. 
(A) C O B R A of 8 B M M C samples from pediatric patients with B lineage ALL. 
(B) C O B R A of 6 B M M C samples from pediatric patients with T lineage A L L 
samples. 
(Key: M: methylated; U: unmethylated) 
B lineage A L L 
(A) 
1 2 3 4 5 6 7 8 
Methylation status U U U M M M M M 
T lineage A L L 
(B) I 2 3 4 5 





Chapter 5 Results 
Figure 5. 10 Cloned bisulfite sequencing analysis of the FBN2 putative promoter in 
pediatric patients with ALL. 
Five P C R clones from 4 B M M C samples from pediatric patients with ALL were 
sequenced. Each row of squares represents one PCR clone, and each square represents 
a CpG site. The methylation status defined by C O B R A and the overall methylation 
level of the FBN2 promoter in each sample was shown in the right column. 
(Key: red square: methylated; white square., unmethylated; M\ methylated; U\ 
unmethylated) 
Childhood ALL 1 COBRA Methylation % 
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5.4.3.2. Semi-quantitative RT-PCR 
After confirming the presence of FBN2 promoter hypermethylation in childhood 
ALL, FBN2 m R N A expression analysis was performed on 27 B M M C samples from 
pediatric patients with A L L using semi-quantitative RT-PCR. Among the samples, 1 
was early pre-B ALL, 14 were common ALL, 7 were pre-B A L L and 5 were T-ALL. 
It was found that the FBN2 m R N A expression in FBN2 promoter hypermethylated 
patient's samples were either loss or down-regulated. The results of m R N A 
expression were concordant with the methylation status as defined by C O B R A 
(Figure 5.11). 
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Figure 5. 11 Semi-quantitative RT-PCR analysis of FBN2 mRNA expression in 27 
BMMC samples from pediatric patients with ALL. 
(Key: M\ methylated; U\ unmethylated) 
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6.1. Genome-wide Screening Approach: MS-AP PCR 
Previous methylation studies in childhood acute lymphoblastic leukemia (ALL) 
involved the investigation of single-gene or multiple-gene, whose approaches usually 
depended on techniques like methylation-sensitive single nucleotide primer extension 
(MS-SNuPE) (Gonzalgo and Jones, 1997)，methylation-sensitive polymerase chain 
reaction (MS-PCR) (Rust et al.’ 1993) or combined bisulfite restriction analysis 
(COBRA) (Xiong and Laird, 1997). Although these techniques are widely used for 
detecting methylation changes at a specific locus, results are often limited to known 
methylation-regulated genes but not novel ones. 
In response to various findings about methylation-induced silencing of tumor 
suppressor genes, genome-wide screening techniques for identifying D N A 
methylation pattern were developed in late 1990’s (Ushijima et al.，1997; Huang et al, 
1999). Therefore, we performed genome-wide D N A methylation screening using 
methylation-sensitive arbitrarily primed polymerase chain reaction (MS-AP PCR) to 
reveal novel cancer-related genes in childhood A L L regulated by CpG island 
methylation. Other genome-wide scanning methodologies include restriction 
107 
Chapter 6 Discussion 
landmark genomic scanning (RLGS) (Kawai et al, 1993), methylation-sensitive 
representational difference analysis (MS-RDA) (Ushijima et al, 1997), methylated 
CpG island amplification coupled with representational difference analysis 
(MCA-RDA) (Toyota et al, 1999), demethylating agent c D N A microarray (Suzuki et 
aL, 2002; Hatada et al, 2006) and differential methylation hybridization (DMH) 
(Huang et aL, 1999). In particular, these methods allow the screening of more than 
thousands of methylated sequences. For examples, RLGS can screen more than 2000 
D N A sequences, whereas M S - R D A and M C A - R D A are able to screen up to 10^ 
D N A sequences. Nevertheless, these methods are technically complicated which 
require a large amount of starting material (DNA and R N A ) and as a result, might 
suffer from interference by repetitive sequences (Ushijima, 2005). 
Conversely, we selected MS-AP P C R because of its simplicity and 
reproducibility. For instance, this screening approach has been employed to identify 
novel hypermethylated genes such as transmembrane protein with EGF-like and two 
follistatin-like domains 2 (TMEFF2), paired box gene 6 {PAX6), pituitary tumor 
apoptosis gene {PTAG) and LIM homeobox 6 gene {LHX6) in colon cancer, bladder 
cancer, pituitary adenomas and head and neck squamous cell carcinoma respectively 
« 
(Liang et al, 2000; Salem et al, 2000; Bahar et al, 2004; Estecio et al., 2006). 
Besides, another similar D N A fingerprinting technique called MS-RF has been used 
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to identify peroxisomal membrane protein 24kDa {PMP24) and endothelin receptor B 
(EDNRB), which are aberrantly hypermethylated in prostate and nasopharyngeal 
carcinomas (Davies, 2002, Lo et al, 2002; W u and Ho, 2004). These findings 
solidified the use of MS-AP P C R as a feasible system for genome-wide methylation 
screening. 
6.2. Sample Selection in this Study 
6.2,1, MS-AP PCR 
Sample preparation and selection are the early steps of genome-wide screening. 
To identify methylation-regulated genes in childhood A L L by MS-AP PCR, 
methylation patterns between leukemic and control samples were compared. 
Moreover, the selection of clinical samples of pediatric patients with A L L was based 
on leukemic blast count and only patients having leukemic blast count >90 % were 
used (blast count >30 % is destined to the diagnosis of ALL). Therefore, 
underestimation of methylation interfered by normal cells can be minimized. 
< 
� 6.2.2. Methylation Studies 
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To prepare clinical samples for methylation studies, it is important to have a 
homogeneous population of cells. B M samples from pediatric patients with A L L may 
contain normal heterogeneous hematopoietic cells and for this reason, the degree of 
methylation may be underestimated. For instance, recent studies revealed there are 
cell-type specific D N A methylations (Futscher et al, 2002; Ohgane et al, 2002; 
Ohgane et al, 2005). To overcome this drawback, we isolated M C (mainly composed 
of leukemic blasts) from B M of pediatric patients with A L L using Ficoll-Paque™ 
PLUS gradient centrifugation. It is more appropriate to select corresponding normal 
B M as control in the methylation analysis. However, normal B M samples are very 
limited. To tackle this problem, D N A from non-malignant B M M C and normal P B M C 
were used as they are generally accepted as a normal control for A L L methylation 
study (Wong et al.，2000; Agirre et al； 2006). 
6.2.3. Studies in ALL Cell Lines 
In order to achieve a preliminary result on the m R N A expression and promoter 
hypermethylation of putative candidate genes, semi-quantitative RT-PCR and C O B R A 
« 
.were performed in selected A L L cell lines, to be benefited from the unlimited supply 
of D N A from cell culturing and homogenous nature of cells. Therefore, A L L cell lines 
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originated from B and T lineages were use for first-line screening prior to clinical 
sample analyses. 
6.3. Methylation Patterns in Childhood ALL 
Our present study provided the first estimation of genome-wide methylation 
changes in childhood ALL. The MS-AP PCR scans the CG-rich regions in the human 
genome and provides information about the methylation changes in individual 
samples. 
Our MS-AP P C R results showed that there was no significant difference of 
methylation frequencies between leukemic group and control group as indicated in 
Table 5.1. This insignificance might be due to the small sample sizes in our studies. 
Conversely, studies in the colon cancer demonstrated a significant reduction in 
5-methycytosine level in adenomas and adenocarcinomas when compared with 
nonnal and paired colonic mucosa (Feinberg et al., 1988). Hence, changes in 
methylation frequency should not be excluded in childhood ALL. 
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6.4. Candidate Genes Selection Strategies in MS-AP PCR 
By using MS-AP PCR, we initially identified 40 evaluable sequences exhibiting 
potential differential methylation changes in childhood A L L (Table 5.1). W e then 
analyzed their genomic localization by U C S C BLAT analysis and we found that 25 of 
40 (63 % ) sequences were mapped to a known or novel gene (Table 5.3). W e further 
selected those sequences that are corresponded to any known or novel m R N A . Among 
the short-listed ones, 13 were identified as transcript-associated CpG islands (located 
at 5' region, coding region or 3' region of a gene) and 10 of them were mapped to 5' 
region of a gene. These 13 sequences were mapped to known genes which have not 
been reported to associate with methylation-induced tumorigenesis in A L L (Figure 
5.4). Recent studies revealed methylation of transcribed regions and regions near 
regulatory elements also involve in the gene expression (Aranyi et al., 2005; Meng et 
al., 2003). Therefore, we did not limit the selection to 5' CpG islands and isolated 
transcript-associated CpG islands during validation. 
Semi-quantitative RT-PCR was performed to examine the m R N A expression 
level of these 13 putative candidate genes. However, 12 of the putative candidates did 
not show a significant change in expression levels in the A L L cell lines. Finally, we 
、 identified a potential candidate gene fibrillin 2 {FBN2). The FBN2 showed 
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down-regulation of m R N A expression in 4 out of 5 A L L cell lines (697, CCRF-CEM; 
M0LT3, Rs4;ll) and was thus subjected to further studies. 
6.5. Fibrillin 2: mRNA Expression and Methylation Studies 
6.5.1 ALL Cell Lines 
Our results demonstrated the aberrant FBN2 promoter hypermethylation was 
concordant to its loss of (CCRF-CEM; M0LT3, Rs4;ll) or down-regulated (697) 
m R N A expression in 5 A L L cell lines. Although promoter hypermethylation was 
detected by C O B R A in REH, cloned bisulfite sequencing revealed not all the clones 
from R E H were methylated; in other words, low methylation density in R E H didn't 
affect the gene expression of FBN2. Demethylating treatment performed by 
5-Aza-dCR on FBN2 methylated and non-expressing cell lines reactivated their FBN2 
m R N A expression, suggesting that the gene silencing in these cell lines were mediated 
by methylation. All these results suggested FBN2 promoter hypermethylation does 
play an important role in childhood ALL. 
6.5.2 Childhood ALL 
6.5.2.1 m R N A Expression and Methylation Studies 
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Our data indicated the loss of FBN2 m R N A expression by promoter 
hypermethylation was a common event in childhood ALL. It was found that the FBN2 
m R N A expression in FBN2 promoter hypermethylated patient's samples were either 
lost or down-regulated (Figure 5.11). 
Scattered methylation of CpG sites were found in some of the non-malignant 
B M M C and normal P B M C control samples by cloned bisulfite sequencing, which 
contributed to 0.51 % , 1.03 % and 3.8 % respectively (Figure 5.7B). The methylation 
frequencies of these controls are much lower than those heavily methylated A L L cell 
lines (Figure 5.7A). In addition, the FBN2 m R N A expression seems not to become 
inactivated under low methylation frequency in such control samples (Figure 5.6B). 
The detection of methylated CpG sites in control samples can be explained by 2 
easons. First, our normal controls were recruited from adult subjects. It is because the 
recruitment of non-malignant B M M C and normal P B M C from pediatric subjects are 
very limited. Hence, all the controls in this study were recruited from non-malignant 
or normal healthy adults. Therefore, detection of methylated alleles in the controls 
might represent pre-malignant changes or be related to age (Tra et al.’ 2004). Second, 
the low percentage of methylation found in normal controls may be arisen from 
f 
random events and did not affect gene expression. It was found that scattered 
‘ methylation of CpG sites is common in cancer control samples but these did not 
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silence the gene expression provided that they are methylated at low frequencies (Liu 
a/., 2006). 
6.5.2.2 Statistical Analysis 
In order to understand the correlation between methylation statuses of FBN2 
between clinical risk groups, we performed statistical analysis to reveal their 
correlation. It is because there is a lack of relevant reports discussing these issues and 
most of the current studies failed to demonstrate a strong correlation between 
methylation status and clinical outcomes of ALL. However, no significance findings 
were found with clinical risk groups, which may probably due to the small sample 
size in our study. 
On the other hand, the aberrant expression of myeloid marker C D 13 was found to 
be statistically significant with hypermethylation status of FBN2 (p=0.043, <0.05 by 
chi-square test). To our knowledge, it is the first study demonstrating such 
relationship between methylation status and aberrant expression of myeloid marker in 
hematological malignancies. However, the contribution of aberrant expression of 
myeloid marker in childhood A L L is still unknown although it is regarded as an 
aberrant phenotype in childhood ALL. It was found that Philadelphia 
、 chromosome-positive A L L patients have a poor prognosis and they are usually 
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associated with higher incidence of aberrant myeloid markers expression (Uckun et 
al., 1998; Boldt et al., 1994). On the contrary, the direct correlation between aberrant 
expression of myeloid markers and disease prognosis of A L L has not been discussed 
in the literatures. The relationship between FBN2 promoter hypermethylation, 
aberrant expression of myeloid marker and patient prognosis needs further 
investigation to confirm the hypothesis. 
6.5.3. Possible Roles of FBN2 in Leukemogenesis 
FBN2 promoter hypermethylation has been demonstrated in non-small cell lung 
cancer (NSCLC) (49 % , 62/126) and pancreatic cancer (75 %，18/24) (Chen et al., 
2005; Hagihara et al., 2004). FBN2 promoter hypermethylation induced 
down-regulation of FBN2 m R N A expression was also observed in N S C L C primary 
tumor and pancreatic cell lines. Reactivation of FBN2 m R N A expression by 
demethylating agent was demonstrated in all FNB2 m R N A non-expressing N S C L C 
cell lines (Chen et al., 2005). These studies suggested that promoter hypermethylation 
and m R N A expression silencing of FBN2 in tumor cells may play important roles in 
tumorigenesis., 
FBN2 gem is located at chromosomal region 5q23.1. It is a large modular 
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extracellular matrix (ECM) glycoprotein and is a key component of E C M . Defect of 
FBN2 is genetically linked to congenital contractural arachnodactyly, a connective 
tissue disorder (Putnam et al, 1995). Since little is known about the role of FBN2 
protein in tumorigenesis or leukemogenesis, we performed literature review to 
characterize the functional domains of FBN2 protein. 
FBN2 protein has 4 well-characterized motifs or domains: R G D peptide, 
transforming growth factor (TGF)-P-binding protein-like domain, epidermal growth 
factor (EGF)-like domain and the calcium binding EGF domain (Sakamoto et al, 
1996; Pereira et al, 1993; Zhang et al.’ 1994). R G D sequence is an 
arginyl-glycyl-aspartyl peptide and is most likely being recognized by the betal 
receptor by serving as a ligand for alpha 3，alpha (v) and betal integrin receptor. 
(Sakamoto et al, 1996; D'Arrigo, 1998). FBN2 protein was found to be biologically 
active for cell adhesion (Ritty et al, 2003) and betal integrin does play an important 
role in the interaction between hematopoietic cell and E C M proteins. The 
involvement of TGF-p signaling pathway in hematopoiesis is still controversial. 
However, TGF-p signaling pathway has an important role in solid tumor like colon, 
pancreatic breast and prostate cancer. Nevertheless, the disruption of TGF-p signaling 
t 
pathway alone doesn't. affect hematopoiesis. Therefore, it may be involved in 
’ progression rather than the initiation of leukemia (Lin et al., 2005). Besides, we didn't 
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find any direct evidence on leukemogenic involvements of EGF-like domain and 
calcium binding-EGF domain of FBN2 protein. 
ALL is a clonal hematopoietic disorder by cell maturation arrest and 
accumulation of malignant lymphoblasts in marrow, lymphatic and non-lymphatic 
tissues and in most cases, leukemic blasts migrate from the B M into PB (Geijtenbeek 
et al, 1999). Therefore, aberrant ALL progenitor proliferation, differentiation and 
homing could be correlated to altered adhesion properties of the ALL blasts. Based on 
the literatures mentioned, the role of FBN2 protein as a betal integrin ligand seems to 
play a particular role in leukemogenesis (Sakamoto et al., 1996; D'Arrigo, 1998). 
Among the adhesion molecules, the integrins of betal family are known to direct 
cell-cell and cell-matrix interaction (Liesvel et al, 1993). Evidence has been provided 
that C D 34 positive stem cells bind either to the bone marrow stroma or the E C M 
protein through the betal integrins (Simmons et al., 1992; Hynes, 1992). Even though 
the exact mechanisms of adhesion of ALL blasts to B M stroma are still unclear, betal 
integrin reorganization sites in FBN2 have been recognized to mediate those cellular 
interactions that are important in ALL biology. Based on this hypothesis, we perform 
statistical analysis to correlate the FBN2 methylation status with the W B C and PB 
I 
-blast. However, from the data we have obtained, the leukemogenic role of FBN2 
seems not related to tumor invasion and metastasis as we expected. The leukemogenic 
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role of FBN2 affect pathway other than tumor invasion and metastasis. Thus, further 
study is required to understand the role of FBN2 in the pathogenesis of childhood 
ALL. To study the role of FBN2, we can simply perform c D N A micorarry analysis on 
FBN2 knock-down A L L cell lines. Target leukemogenic pathway affected by FBN2 
can be identified by comparing the gene expression among the FBN2 positive and 
FBN2 negative cell lines. 
6.6. Clinical Application of FBN2 Aberrant Methylation 
6.6.1. Tumor Markers 
The identification of differentially methylated patterns has potential clinical 
significance in being a tumor marker. For example, the methylation differences 
between tumor and normal cells can be used to detect the presence of tumor cells in 
biopsy specimens or to identify tumor-derived D N A in blood samples (Esteller et al, 
1999; Wong et al., 1999; Kawakami et al.’ 2000). Cancer spedfic methylation 
detection has been described in sputum biopsy for lung cancer and pancreatic juice for 
pancreatic cancer (Laird, 2003; Belinsky, 2004; Matsubayashi et al., 2006). In this 
application, methylation is not necessary to induce gene silencing but is required to be 
specific to tumor cells or to have a correlation with clinical outcome of the patients. 
‘ So far, no methylation-specific tumor markers have been found in childhood ALL. In 
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the succeeding year, this application has an increasing importance even the 
methylation does not induce gene silencing. 
Methylation of specific genes or methylation profiling can also be linked to 
disease prognosis and response to chemotherapy. Promoter hypermethylation of 
death-associated protein kinase 1 (DAPK) is associated to recurrent bladder cancer 
(Tada et al., 2002). Besides, the inactivation of 0^-Methylguanine DNA 
methyltransferase (MGMT) through promoter hypermethylation leads to the increase 
of sensitivity of alkylating drugs used in chemotherapy in treating gliomas (Esteller et 
al., 2000). 
The criteria of FBN2 in being a tumor marker have been demonstrated in our 
study, as implied from the high methylation frequency (69 % ) observed in childhood 
A L L patients. Therefore, the promoter hypermethylation of FBN2 can be regarded as 
a suggestive candidate as a tumor marker of childhood ALL. Due to the sensitivity of 
D N A molecular studies, the detection of remaining leukemic blasts or the possibilities 
of relapse, such as the occurrence of minimal residual disease (MRD) would become 
more precise. In particular, the down-regulation of FBN2 m R N A was found to be 
associated with its promoter hypermethylation. This may affect its protein expression 
and hence alters specific physiological pathway, on the other hand, affecting the 
、 prognosis of a patient. Hopefully, the role of FBN2 can stride forward to act as a 
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prognostic marker when its functional characterization has demonstrated in ALL 
leukemogenesis. 
6.6.2. Use of Demethylating Drugs in Chemotherapy 
DNA-methyltransferases (DNMT) and histonedeacetylase (HDAC) are the 2 
major drug targets for epigenetic inhibition. These provide a powerful rationale for 
using azanucleosides as a novel means of pharmacologic targeting of cancer cells that 
is distinct from low-dose chemotherapy. Decitabine (5-aza-2‘ -deoxycytidine), a 
cytosine analogue, has selective D N A demethylating activity at low doses (Momparler, 
2005). A clinical development program with low-dose decitabine in malignant 
diseases is currently focused on myelodysplastic syndrome (MDS)，acute myeloid 
leukemia (AML) and chronic myeloid leukemia (CML) (Issa et al, 2004; Gore et al., 
2006). The optimal use of decitabine may be used in combination with H D A C 
inhibitors to promote gene expression. Optimized decitabine doses and combinations 
with other epigenetic therapies can be used at minimally toxic doses which provide 
potentially safer therapeutic options and introduce novel combination therapies (Gore, 
2005). 
« 
Furthermore, the in vivo demethylating action has been demonstrated by our 
study using A L L cell lines as model. Hopefully, the application of epigenetic drugs 
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can be successfully applied to various cancers including childhood ALL. 
6.7. Limitations of Methylation Studies 
6.7.1. MS-AP PCR 
Genome-wide methylation screening is a useful technique to identify difference 
in methylation patterns between cell types. However, it is important to emphasize its 
potential pitfalls. MS-AP P C R suffered from a few limitations. First, the numbers of 
bands analyzed on a single gel are limited. Second, only small sample size can be 
achieved and the number of samples per group is small. The small sample size does 
not allow sounding statistical analysis of the correlation between methylation changes 
and their clinical parameters to be performed. Therefore, increases in sample size 
would facilitate the analysis of the methylation changes. Lastly, MS-AP P C R has a 
relatively low resolution compared with other known techniques. However, we still 
utilize the MS-AP P C R platform because of the easy setup, simple technique and less 
labour work. 
« 
�6.7.2. Techniques Used in Methylation Study 
C O B R A and bisulfite sequencing were performed in the candidate gene 
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methylation analysis. Though C O B R A provides a simple and rapid scanning of 
methylation status, it may omit and underestimate methylation changes outside the 
restriction enzyme recognition sites. Therefore, more than one restriction enzyme can 
be included in C O B R A to increase the number of CpG sites being detected. Moreover, 
this problem can be solved by cloned bisulfite sequencing, which however, it is labor 
intensive and more tedious, but it provides information on the methylation status of 
every cytosine residue within the target sequence. Hence, using both methods can 
facilitate a rapid and promising methylation analysis. 
6.7.3. Problems in Methylation Study 
It has been recognized that methylation in cancer cells frequently occurr in CpG 
islands outside promoter region which do not repress gene transcription. An example 
of this phenomenon is the hypermethylation of CpG island in exon 5 of PAX6 in colon 
cancer (Salem et al., 2000). Since not all CpG islands are localized to the 5' promoter 
region, methylation of these CpG islands usually may not regulate respective gene 
transcriptions. Moreover, promoter hypermethylation of a gene occuring in the 
t 
、promoter region may not be regarded as a tumor suppressor gene (Wutz et al, 1997; 
Gonzalgo et al, 1998). Even in normal cell, methylation of specific CpG islands 
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frequently occurs. 
Genome-wide methylation screening usually results in isolation of numerous 
differentially methylated D N A fragments. To correlate the methylation status with a 
potential tumor suppressor gene, several verification steps are necessary. First, 
promoter hypermethylation associated with gene silencing must be identified. Second, 
the expression of a gene in normal cell must be confirmed. Third, the role of 
methylation in this particular gene can be verified by treating cells with demethylating 
agent. Finally, the functional role of the gene should be demonstrated in the 
participation of tumorigenesis. These made the identification of tumor suppressor 
gene by genome-wide scanning technique more complicated and time-consuming 
through a series of validation. Nevertheless, this problem is not restricted to MS-AP 
PCR. Other methylation screening approaches also identified the CpG-rich sequences 
outside 5' promoter region (Davies 2002; Liang et al, 2002). 
Although promoter hypermethylation has been demonstrated in various types of 
human cancers, hypomethylation is consistently observed (Hoffmann and Schulz, 
2005). Hypomethylation mainly occurs in repetitive sequence, where high rates of 
mutation and polymorphism are observed. The analysis on quantifying 
hypomethylation is very difficult because large amount of D N A has to be used for this 
kind of repetitive sequence (Santourlidis et al, 1999). In conclusion, the use of 
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hypomethylation as disease markers will therefore be very difficult. 
6.8. Future Studies 
In order to characterize the function of FBN2 in childhood A L L pathogenesis, 
FBN2 protein expression should be done. It can be achieved by either 
Western-blotting, immuno-histochemistry or flow cytometry. Once the correlations 
between promoter hypermethylation and FBN2 protein expression have been verified, 
functional characterization of FBN2 protein can be performed to evaluate the role of 
FBN2 in leukemogenesis. It can be done by electroporation of FBN2 construct into 
FBN2 protein deficient A L L cell lines. The Nucleofection® (Amaxa 
Biosystems，Geithersburg，MD) is a newly developed technology for efficient 
non-viral transfection of suspension cell types. The transfection of recombinant 
plasmid into human CD34+ hematopoietic cell has been successfully demonstrated 
(Takeda et al, 2006). The effect of re-expression of FBN2 can be monitored by cell 
cycle analysis, apoptosis assay and cell proliferation assay. 
Moreover, to further confirm the possible significance of FBN2 promoter 
hypermethylation in childhood A L L diagnosis or prognosis, a larger study with more 
detailed clinical outcomes of each patient is essential to understand the actual 
‘ clinico-pathological role of FBN2. Once the prognostic value of FBN2 is established, 
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individualized treatment can be applied on patients with FBN2 promoter 
hypermethylation by epigenetic therapy or other specific chemotherapy. 
« 
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Chapter 7 Conclusion 
This is the first study investigating the genome-wide D N A methylation changes 
in childhood A L L patients. Our results demonstrated the feasibility of MS-AP PCR in 
the identification of methylation-regulated genes. For instance, we have successfully 
demonstrated the correlation between FBN2 promoter hypermethylation with its 
m R N A down-regulation in various subtypes of childhood ALL. 
FBN2 may be added to the list of methylation associated genes in childhood 
ALL as implied from the observable methylation frequency. On the other hand, these 
data suggested the use of FBN2 promoter hypermethylation as a potential tumor 
marker for childhood ALL. 
Nevertheless, the potential biological functions of FBN2 protein in human 
leukemogenesis remain to be elucidated. Functional characterization on the role of 
FBN2's biological functions may provide more information to understand the 
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